BRAF
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
Log-Odds: S Sites / S Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O14974 | S695 | Sugiyama | PPP1R12A MBS MYPT1 | DEEsEsQRKARSRQARQsRRstQGVtLtDLQEAEKtIGRSR |
| P04049 | S357 | Sugiyama | RAF1 RAF | DssyyWEIEASEVMLSTRIGsGsFGtVYKGKWHGDVAVKIL |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P10398 | S528 | Sugiyama | ARAF ARAF1 PKS PKS2 | PYSHIGCRDQIIFMVGRGYLsPDLSKISSNCPKAMRRLLSD |
| P13639 | S38 | Sugiyama | EEF2 EF2 | NIRNMsVIAHVDHGKStLtDsLVCKAGIIAsARAGEtRFtD |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P15056 | S147 | iPTMNet | BRAF BRAF1 RAFB1 | SLSVLPSSLSVFQNPTDVARsNPKsPQKPIVRVFLPNKQRT |
| P15056 | S151 | iPTMNet | BRAF BRAF1 RAFB1 | LPSSLSVFQNPTDVARsNPKsPQKPIVRVFLPNKQRTVVPA |
| P15056 | S419 | iPTMNet | BRAF BRAF1 RAFB1 | sAtPPAsLPGSLTNVKALQKsPGPQRERKsssssEDRNRMK |
| P15056 | S446 | Sugiyama | BRAF BRAF1 RAFB1 | RKsssssEDRNRMKtLGRRDssDDWEIPDGQITVGQRIGsG |
| P15056 | S465 | SIGNOR|PSP|Sugiyama | BRAF BRAF1 RAFB1 | DssDDWEIPDGQITVGQRIGsGsFGtVYKGKWHGDVAVKML |
| P15056 | S467 | SIGNOR|PSP | BRAF BRAF1 RAFB1 | sDDWEIPDGQITVGQRIGsGsFGtVYKGKWHGDVAVKMLNV |
| P15056 | S614 | SIGNOR|EPSD|PSP | BRAF BRAF1 RAFB1 | DFGLAtVKsRWsGsHQFEQLsGSILWMAPEVIRMQDKNPYS |
| P15056 | S675 | Sugiyama | BRAF BRAF1 RAFB1 | PYSNINNRDQIIFMVGRGYLsPDLSKVRSNCPKAMKRLMAE |
| P15056 | S750 | iPTMNet | BRAF BRAF1 RAFB1 | EPSLNRAGFQTEDFSLYACAsPKtPIQAGGYGAFPVH____ |
| P15056 | T373 | GPS6|iPTMNet|EPSD|PSP | BRAF BRAF1 RAFB1 | HRNQFGQRDRsssAPNVHINtIEPVNIDDLIRDQGFRGDGG |
| P19634 | T653 | EPSD|PSP | SLC9A1 APNH1 NHE1 | KILRNNLQKTRQRLRsyNRHtLVADPyEEAWNQMLLRRQKA |
| P33981 | S281 | EPSD|PSP | TTK MPS1 MPS1L1 | QTNKTKQSCPFGRVPVNLLNsPDCDVKtDDsVVPCFMKRQT |
| P33981 | S436 | EPSD|PSP | TTK MPS1 MPS1L1 | VNTEQKHTTFEQPVFSVSKQsPPISTSKWFDPKSICKtPss |
| P36507 | S222 | SIGNOR|EPSD|PSP | MAP2K2 MEK2 MKK2 PRKMK2 | VNSRGEIKLCDFGVsGQLIDsMANsFVGtRSYMAPERLQGT |
| P36507 | S226 | SIGNOR|EPSD|PSP | MAP2K2 MEK2 MKK2 PRKMK2 | GEIKLCDFGVsGQLIDsMANsFVGtRSYMAPERLQGTHYSV |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P49840 | Y279 | Sugiyama | GSK3A | LKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTS |
| P49841 | Y216 | Sugiyama | GSK3B | LKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTS |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P68104 | S21 | SIGNOR|EPSD|PSP | EEF1A1 EEF1A EF1A LENG7 | MGKEKtHINIVVIGHVDsGKstttGHLIyKCGGIDKRTIEK |
| P68104 | T88 | SIGNOR|EPSD|PSP | EEF1A1 EEF1A EF1A LENG7 | ERGITIDISLWKFEtsKyyVtIIDAPGHRDFIKNMITGTSQ |
| P68363 | S439 | Sugiyama | TUBA1B | SEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy________ |
| Q02750 | S218 | SIGNOR|EPSD|PSP | MAP2K1 MEK1 PRKMK1 | VNSRGEIKLCDFGVsGQLIDsMANsFVGtRSYMsPERLQGT |
| Q02750 | S222 | SIGNOR|EPSD|PSP | MAP2K1 MEK1 PRKMK1 | GEIKLCDFGVsGQLIDsMANsFVGtRSYMsPERLQGTHYSV |
| Q02750 | S248 | SIGNOR | MAP2K1 MEK1 PRKMK1 | SYMsPERLQGTHYSVQsDIWsMGLsLVEMAVGRYPIPPPDA |
| Q02750 | S252 | SIGNOR | MAP2K1 MEK1 PRKMK1 | PERLQGTHYSVQsDIWsMGLsLVEMAVGRYPIPPPDAKELE |
| Q05639 | S21 | SIGNOR|EPSD|PSP | EEF1A2 EEF1AL STN | MGKEKtHINIVVIGHVDsGKstttGHLIyKCGGIDKRTIEK |
| Q14432 | T311 | Sugiyama | PDE3A | RsssVVsAEMSGCSSKSHRRtsLPCIPREQLMGHSEWDHKR |
| Q15080 | S67 | Sugiyama | NCF4 SH3PXD4 | TKGGSKYLIYRRYRQFHALQsKLEERFGPDSKSSALACTLP |
| Q71U36 | S439 | Sugiyama | TUBA1A TUBA3 | SEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy________ |
| Q8NFD5 | S1744 | Sugiyama | ARID1B BAF250B DAN15 KIAA1235 OSA2 | ALDTINILLYDDSTVATFNLsQLSGFLELLVEYFRKCLIDI |
| Q92934 | S118 | EPSD|PSP | BAD BBC6 BCL2L8 | RsAPPNLWAAQRYGRELRRMsDEFVDsFKKGLPRPKsAGtA |
| Q92934 | S134 | EPSD|PSP | BAD BBC6 BCL2L8 | LRRMsDEFVDsFKKGLPRPKsAGtATQMRQSSSWTRVFQsW |
| Q92934 | S75 | EPSD|PSP | BAD BBC6 BCL2L8 | PTSSSHHGGAGAVEIRsRHssyPAGtEDDEGMGEEPsPFRG |
| Q92934 | S99 | EPSD|PSP | BAD BBC6 BCL2L8 | GtEDDEGMGEEPsPFRGRsRsAPPNLWAAQRYGRELRRMsD |
| Q9H9S0 | S68 | PSP | NANOG | TETVsPLPSSMDLLIQDsPDsSTsPKGKQPtsAEKSVAKKE |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 6.305453e-09 | 8.200 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.987519e-07 | 6.702 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 4.297901e-07 | 6.367 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.457342e-06 | 5.836 | 1 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.818146e-06 | 5.550 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 4.223525e-05 | 4.374 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.127510e-04 | 3.948 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 2.128552e-04 | 3.672 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.957844e-04 | 3.708 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 4.370000e-04 | 3.360 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 4.876639e-04 | 3.312 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 6.449015e-04 | 3.191 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 6.449015e-04 | 3.191 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 6.192854e-04 | 3.208 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 6.877655e-04 | 3.163 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 7.210527e-04 | 3.142 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 7.420341e-04 | 3.130 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 7.581732e-04 | 3.120 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 8.880636e-04 | 3.052 | 1 | 1 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.017759e-03 | 2.992 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.099420e-03 | 2.959 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.075221e-03 | 2.969 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.138247e-03 | 2.944 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.227442e-03 | 2.911 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.357489e-03 | 2.867 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.529683e-03 | 2.815 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.817465e-03 | 2.741 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 2.072908e-03 | 2.683 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 1.940890e-03 | 2.712 | 1 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.777652e-03 | 2.750 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 2.072908e-03 | 2.683 | 0 | 0 |
| M Phase | R-HSA-68886 | 2.063577e-03 | 2.685 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.783838e-03 | 2.749 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.012693e-03 | 2.696 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 1.783838e-03 | 2.749 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.799691e-03 | 2.745 | 1 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 1.867245e-03 | 2.729 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 2.419932e-03 | 2.616 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.426756e-03 | 2.615 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.313295e-03 | 2.636 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 2.419932e-03 | 2.616 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 2.747116e-03 | 2.561 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 2.668024e-03 | 2.574 | 1 | 1 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.668024e-03 | 2.574 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 2.747116e-03 | 2.561 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 2.747116e-03 | 2.561 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.947300e-03 | 2.531 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 3.197838e-03 | 2.495 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 3.388874e-03 | 2.470 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.351910e-03 | 2.475 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 3.327521e-03 | 2.478 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.800828e-03 | 2.420 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.044401e-03 | 2.393 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 4.742930e-03 | 2.324 | 1 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 4.742930e-03 | 2.324 | 1 | 1 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 4.742930e-03 | 2.324 | 1 | 1 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 4.742930e-03 | 2.324 | 1 | 1 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 5.161807e-03 | 2.287 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 5.133550e-03 | 2.290 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 5.199158e-03 | 2.284 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 5.199158e-03 | 2.284 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 5.799630e-03 | 2.237 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 5.799630e-03 | 2.237 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 5.799630e-03 | 2.237 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 5.799630e-03 | 2.237 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 5.161807e-03 | 2.287 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 5.799630e-03 | 2.237 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 4.974515e-03 | 2.303 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 6.004669e-03 | 2.222 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 5.987054e-03 | 2.223 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 6.004669e-03 | 2.222 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 6.219973e-03 | 2.206 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 6.338291e-03 | 2.198 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 6.477576e-03 | 2.189 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 6.515538e-03 | 2.186 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 6.805963e-03 | 2.167 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 7.059526e-03 | 2.151 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 6.972214e-03 | 2.157 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 7.135130e-03 | 2.147 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 7.374652e-03 | 2.132 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 7.995974e-03 | 2.097 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 7.571068e-03 | 2.121 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 7.571068e-03 | 2.121 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 7.995974e-03 | 2.097 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 7.995974e-03 | 2.097 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 7.789887e-03 | 2.108 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 8.008257e-03 | 2.096 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 8.008257e-03 | 2.096 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 8.654812e-03 | 2.063 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 8.729154e-03 | 2.059 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 8.384355e-03 | 2.077 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 8.294939e-03 | 2.081 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 8.744133e-03 | 2.058 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 9.360656e-03 | 2.029 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 9.360656e-03 | 2.029 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 9.884298e-03 | 2.005 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 9.065107e-03 | 2.043 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 9.065107e-03 | 2.043 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 9.489809e-03 | 2.023 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 9.728200e-03 | 2.012 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 9.360656e-03 | 2.029 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 9.362795e-03 | 2.029 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 9.884298e-03 | 2.005 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 9.065107e-03 | 2.043 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 1.023267e-02 | 1.990 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.023267e-02 | 1.990 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.024618e-02 | 1.989 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 1.032494e-02 | 1.986 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.150319e-02 | 1.939 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 1.150319e-02 | 1.939 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 1.122552e-02 | 1.950 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 1.098071e-02 | 1.959 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.068432e-02 | 1.971 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.115574e-02 | 1.953 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 1.070931e-02 | 1.970 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.162705e-02 | 1.935 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.191200e-02 | 1.924 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.201310e-02 | 1.920 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.240441e-02 | 1.906 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.579013e-02 | 1.802 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.579013e-02 | 1.802 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.579013e-02 | 1.802 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.579013e-02 | 1.802 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.579013e-02 | 1.802 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.579013e-02 | 1.802 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.579013e-02 | 1.802 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 1.579013e-02 | 1.802 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.579013e-02 | 1.802 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.579013e-02 | 1.802 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.579013e-02 | 1.802 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.579013e-02 | 1.802 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.579013e-02 | 1.802 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.597606e-02 | 1.797 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 1.563015e-02 | 1.806 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 1.563015e-02 | 1.806 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.335258e-02 | 1.874 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.597606e-02 | 1.797 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.437067e-02 | 1.843 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.437067e-02 | 1.843 | 1 | 1 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.580673e-02 | 1.801 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.374388e-02 | 1.862 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 1.288109e-02 | 1.890 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.580673e-02 | 1.801 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 1.335258e-02 | 1.874 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 1.335258e-02 | 1.874 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.653209e-02 | 1.782 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 1.667826e-02 | 1.778 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.695363e-02 | 1.771 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 1.770125e-02 | 1.752 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 1.770125e-02 | 1.752 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.773236e-02 | 1.751 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.773236e-02 | 1.751 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.850549e-02 | 1.733 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.861620e-02 | 1.730 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.152007e-02 | 1.667 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.152007e-02 | 1.667 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.899487e-02 | 1.721 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.955006e-02 | 1.709 | 1 | 1 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.955006e-02 | 1.709 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.947580e-02 | 1.711 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.032130e-02 | 1.692 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 2.143632e-02 | 1.669 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.991398e-02 | 1.701 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.957934e-02 | 1.708 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 2.152007e-02 | 1.667 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 1.991398e-02 | 1.701 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.200221e-02 | 1.658 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 2.201853e-02 | 1.657 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.273521e-02 | 1.643 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.363280e-02 | 1.626 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 2.384555e-02 | 1.623 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 2.392124e-02 | 1.621 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 2.392124e-02 | 1.621 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 2.392124e-02 | 1.621 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 2.458266e-02 | 1.609 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 2.458266e-02 | 1.609 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 2.458266e-02 | 1.609 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.479272e-02 | 1.606 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 2.967122e-02 | 1.528 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 2.587338e-02 | 1.587 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 2.825083e-02 | 1.549 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.676063e-02 | 1.573 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 2.967591e-02 | 1.528 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.958468e-02 | 1.529 | 1 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.594560e-02 | 1.586 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 2.825083e-02 | 1.549 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.555418e-02 | 1.593 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 2.587338e-02 | 1.587 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 2.825083e-02 | 1.549 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 2.676063e-02 | 1.573 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 2.991347e-02 | 1.524 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 3.076791e-02 | 1.512 | 1 | 1 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 3.219459e-02 | 1.492 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 3.219459e-02 | 1.492 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 3.219459e-02 | 1.492 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 3.219459e-02 | 1.492 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 3.340248e-02 | 1.476 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 3.340248e-02 | 1.476 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 3.340248e-02 | 1.476 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 3.340248e-02 | 1.476 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 3.340248e-02 | 1.476 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 3.340248e-02 | 1.476 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 3.342718e-02 | 1.476 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 3.471881e-02 | 1.459 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 3.527094e-02 | 1.453 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 3.633013e-02 | 1.440 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 3.633013e-02 | 1.440 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 4.409202e-02 | 1.356 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 4.409202e-02 | 1.356 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 4.137470e-02 | 1.383 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 4.328909e-02 | 1.364 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.406747e-02 | 1.356 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.898095e-02 | 1.409 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 4.137470e-02 | 1.383 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 4.044891e-02 | 1.393 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 4.177711e-02 | 1.379 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 4.137470e-02 | 1.383 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 4.227978e-02 | 1.374 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 4.235594e-02 | 1.373 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 4.227978e-02 | 1.374 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 4.249780e-02 | 1.372 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 4.249780e-02 | 1.372 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 3.958837e-02 | 1.402 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.715624e-02 | 1.430 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 4.075772e-02 | 1.390 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 4.109372e-02 | 1.386 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 3.764385e-02 | 1.424 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 4.448709e-02 | 1.352 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 4.547776e-02 | 1.342 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 4.552824e-02 | 1.342 | 0 | 0 |
| Defective F9 secretion | R-HSA-9673218 | 4.621962e-02 | 1.335 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 4.638986e-02 | 1.334 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 4.649221e-02 | 1.333 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 4.797263e-02 | 1.319 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 4.831285e-02 | 1.316 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 4.831285e-02 | 1.316 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 5.048965e-02 | 1.297 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 5.129420e-02 | 1.290 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 5.129420e-02 | 1.290 | 1 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 5.489184e-02 | 1.260 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 5.505243e-02 | 1.259 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 5.559989e-02 | 1.255 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 5.559989e-02 | 1.255 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 5.559989e-02 | 1.255 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 5.579177e-02 | 1.253 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 5.579177e-02 | 1.253 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 5.585822e-02 | 1.253 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 5.585822e-02 | 1.253 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 5.585822e-02 | 1.253 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 5.705866e-02 | 1.244 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 5.756478e-02 | 1.240 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 6.259977e-02 | 1.203 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 7.341010e-02 | 1.134 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 6.481731e-02 | 1.188 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 6.972764e-02 | 1.157 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 6.822112e-02 | 1.166 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 7.254074e-02 | 1.139 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.254074e-02 | 1.139 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 6.725578e-02 | 1.172 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 7.341010e-02 | 1.134 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 6.532510e-02 | 1.185 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 6.867776e-02 | 1.163 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 6.016209e-02 | 1.221 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 6.822112e-02 | 1.166 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 7.210688e-02 | 1.142 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 6.138161e-02 | 1.212 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 6.560422e-02 | 1.183 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 7.341010e-02 | 1.134 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 6.138161e-02 | 1.212 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 6.004293e-02 | 1.222 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 6.402185e-02 | 1.194 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 7.341010e-02 | 1.134 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.059906e-02 | 1.218 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 6.725578e-02 | 1.172 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 5.999618e-02 | 1.222 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 7.483741e-02 | 1.126 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 7.483741e-02 | 1.126 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 7.483741e-02 | 1.126 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 7.483741e-02 | 1.126 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 7.483741e-02 | 1.126 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 7.483741e-02 | 1.126 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 7.487670e-02 | 1.126 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 7.903126e-02 | 1.102 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 7.903126e-02 | 1.102 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.983961e-02 | 1.098 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 8.014487e-02 | 1.096 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 8.214120e-02 | 1.085 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 8.214120e-02 | 1.085 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 8.214120e-02 | 1.085 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 8.214120e-02 | 1.085 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 9.030566e-02 | 1.044 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 9.030566e-02 | 1.044 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 9.030566e-02 | 1.044 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 9.030566e-02 | 1.044 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 9.030566e-02 | 1.044 | 0 | 0 |
| TGFBR2 MSI Frameshift Mutants in Cancer | R-HSA-3642279 | 9.030566e-02 | 1.044 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 9.030566e-02 | 1.044 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 9.030566e-02 | 1.044 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 9.030566e-02 | 1.044 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 9.030566e-02 | 1.044 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 9.030566e-02 | 1.044 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 9.030566e-02 | 1.044 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 9.644014e-02 | 1.016 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 1.113789e-01 | 0.953 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 8.653866e-02 | 1.063 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 8.560209e-02 | 1.068 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 9.350096e-02 | 1.029 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.113789e-01 | 0.953 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 8.653866e-02 | 1.063 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.081872e-01 | 0.966 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 9.348312e-02 | 1.029 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 9.350096e-02 | 1.029 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 8.653866e-02 | 1.063 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.350096e-02 | 1.029 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 9.712247e-02 | 1.013 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 8.787913e-02 | 1.056 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.026512e-01 | 0.989 | 1 | 0 |
| Mismatch Repair | R-HSA-5358508 | 9.712247e-02 | 1.013 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.113789e-01 | 0.953 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 8.787913e-02 | 1.056 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 9.134255e-02 | 1.039 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 9.644014e-02 | 1.016 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 9.644014e-02 | 1.016 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 1.113789e-01 | 0.953 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 1.113789e-01 | 0.953 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 9.644014e-02 | 1.016 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 1.067408e-01 | 0.972 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.094273e-01 | 0.961 | 1 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 1.067408e-01 | 0.972 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 8.653866e-02 | 1.063 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 9.239058e-02 | 1.034 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 9.350096e-02 | 1.029 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 1.113789e-01 | 0.953 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 1.113789e-01 | 0.953 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 1.113789e-01 | 0.953 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 9.350096e-02 | 1.029 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 8.787913e-02 | 1.056 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.067408e-01 | 0.972 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 8.653866e-02 | 1.063 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 8.641547e-02 | 1.063 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 8.904185e-02 | 1.050 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 8.699731e-02 | 1.060 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 9.833253e-02 | 1.007 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.110902e-01 | 0.954 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.067408e-01 | 0.972 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 9.644014e-02 | 1.016 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.033035e-01 | 0.986 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.081872e-01 | 0.966 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 8.511918e-02 | 1.070 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 9.723024e-02 | 1.012 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 1.113789e-01 | 0.953 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 9.134255e-02 | 1.039 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 9.268226e-02 | 1.033 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 8.641547e-02 | 1.063 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 9.644014e-02 | 1.016 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 9.712247e-02 | 1.013 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 1.016420e-01 | 0.993 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 1.121075e-01 | 0.950 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.125234e-01 | 0.949 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 1.125234e-01 | 0.949 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.125234e-01 | 0.949 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 1.323565e-01 | 0.878 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 1.323565e-01 | 0.878 | 0 | 0 |
| Defective HK1 causes hexokinase deficiency (HK deficiency) | R-HSA-5619056 | 1.323565e-01 | 0.878 | 0 | 0 |
| XAV939 stabilizes AXIN | R-HSA-5545619 | 1.323565e-01 | 0.878 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 1.323565e-01 | 0.878 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 1.323565e-01 | 0.878 | 0 | 0 |
| Defective TPMT causes TPMT deficiency | R-HSA-5578995 | 1.323565e-01 | 0.878 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 1.323565e-01 | 0.878 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 1.724659e-01 | 0.763 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 1.724659e-01 | 0.763 | 0 | 0 |
| Defective factor IX causes thrombophilia | R-HSA-9672383 | 1.724659e-01 | 0.763 | 0 | 0 |
| Defective cofactor function of FVIIIa variant | R-HSA-9672396 | 1.724659e-01 | 0.763 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 1.724659e-01 | 0.763 | 0 | 0 |
| Defective F9 variant does not activate FX | R-HSA-9673202 | 1.724659e-01 | 0.763 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 1.724659e-01 | 0.763 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 2.107235e-01 | 0.676 | 0 | 0 |
| The IPAF inflammasome | R-HSA-844623 | 2.107235e-01 | 0.676 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 2.107235e-01 | 0.676 | 0 | 0 |
| Defective ABCD4 causes MAHCJ | R-HSA-5683329 | 2.107235e-01 | 0.676 | 0 | 0 |
| Signalling to STAT3 | R-HSA-198745 | 2.107235e-01 | 0.676 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 2.107235e-01 | 0.676 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 2.107235e-01 | 0.676 | 0 | 0 |
| Defective gamma-carboxylation of F9 | R-HSA-9673240 | 2.107235e-01 | 0.676 | 0 | 0 |
| Alternative complement activation | R-HSA-173736 | 2.472147e-01 | 0.607 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 2.472147e-01 | 0.607 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.472147e-01 | 0.607 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 2.472147e-01 | 0.607 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 2.472147e-01 | 0.607 | 0 | 0 |
| Defective MAT1A causes MATD | R-HSA-5579024 | 2.472147e-01 | 0.607 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.820208e-01 | 0.550 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 2.820208e-01 | 0.550 | 0 | 0 |
| Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA) | R-HSA-5619067 | 2.820208e-01 | 0.550 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 2.820208e-01 | 0.550 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 1.591733e-01 | 0.798 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.758431e-01 | 0.755 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 1.758431e-01 | 0.755 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 3.152196e-01 | 0.501 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 3.152196e-01 | 0.501 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 3.152196e-01 | 0.501 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 3.152196e-01 | 0.501 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 1.167132e-01 | 0.933 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.927698e-01 | 0.715 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.927698e-01 | 0.715 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 1.376339e-01 | 0.861 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.376339e-01 | 0.861 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 1.376339e-01 | 0.861 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 2.098942e-01 | 0.678 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 2.098942e-01 | 0.678 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 3.468852e-01 | 0.460 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 3.468852e-01 | 0.460 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 1.485389e-01 | 0.828 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 1.597112e-01 | 0.797 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.711293e-01 | 0.767 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 2.445229e-01 | 0.612 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 1.320025e-01 | 0.879 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 1.403828e-01 | 0.853 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 2.619322e-01 | 0.582 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 1.946171e-01 | 0.711 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.066450e-01 | 0.685 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.066450e-01 | 0.685 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 2.793480e-01 | 0.554 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.793480e-01 | 0.554 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.188349e-01 | 0.660 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 2.188349e-01 | 0.660 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 2.188349e-01 | 0.660 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.188349e-01 | 0.660 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.188349e-01 | 0.660 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.967327e-01 | 0.528 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 2.967327e-01 | 0.528 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 2.967327e-01 | 0.528 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 2.311671e-01 | 0.636 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 2.311671e-01 | 0.636 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.851735e-01 | 0.732 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 3.140520e-01 | 0.503 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 3.140520e-01 | 0.503 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 3.140520e-01 | 0.503 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 2.561811e-01 | 0.591 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 2.140007e-01 | 0.670 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 3.312747e-01 | 0.480 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 3.312747e-01 | 0.480 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 3.312747e-01 | 0.480 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 3.312747e-01 | 0.480 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 3.312747e-01 | 0.480 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 1.549219e-01 | 0.810 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 1.892202e-01 | 0.723 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 2.055212e-01 | 0.687 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.818805e-01 | 0.740 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 2.943041e-01 | 0.531 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 2.541461e-01 | 0.595 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 2.541461e-01 | 0.595 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 3.071041e-01 | 0.513 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 3.327479e-01 | 0.478 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 3.327479e-01 | 0.478 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.837116e-01 | 0.736 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 3.167331e-01 | 0.499 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 3.273190e-01 | 0.485 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 3.273190e-01 | 0.485 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 3.379255e-01 | 0.471 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 2.608219e-01 | 0.584 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 1.267814e-01 | 0.897 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 2.066450e-01 | 0.685 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.124115e-01 | 0.673 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 1.667185e-01 | 0.778 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.815394e-01 | 0.550 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 3.071041e-01 | 0.513 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.414800e-01 | 0.617 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 2.271618e-01 | 0.644 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.188683e-01 | 0.925 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.293916e-01 | 0.888 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.747700e-01 | 0.561 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.428249e-01 | 0.845 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 2.820208e-01 | 0.550 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 3.199237e-01 | 0.495 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 3.327479e-01 | 0.478 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 1.376339e-01 | 0.861 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 1.485389e-01 | 0.828 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.320025e-01 | 0.879 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 1.827716e-01 | 0.738 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 2.188349e-01 | 0.660 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 2.943041e-01 | 0.531 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.472147e-01 | 0.607 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.815394e-01 | 0.550 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.455627e-01 | 0.461 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 3.420075e-01 | 0.466 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 2.815394e-01 | 0.550 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 3.468852e-01 | 0.460 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 1.827716e-01 | 0.738 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.332854e-01 | 0.875 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 1.270181e-01 | 0.896 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.927698e-01 | 0.715 | 1 | 1 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 2.820208e-01 | 0.550 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 2.820208e-01 | 0.550 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 2.820208e-01 | 0.550 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 2.820208e-01 | 0.550 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 2.820208e-01 | 0.550 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 3.152196e-01 | 0.501 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 2.619322e-01 | 0.582 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 2.436220e-01 | 0.613 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 2.815394e-01 | 0.550 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 2.956573e-01 | 0.529 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 3.344687e-01 | 0.476 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 1.403828e-01 | 0.853 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 3.106017e-01 | 0.508 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.679970e-01 | 0.775 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.927698e-01 | 0.715 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 1.403828e-01 | 0.853 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.249743e-01 | 0.903 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 2.089386e-01 | 0.680 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.644437e-01 | 0.784 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 3.152196e-01 | 0.501 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 3.468852e-01 | 0.460 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 2.271618e-01 | 0.644 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.238372e-01 | 0.907 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.946171e-01 | 0.711 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.312747e-01 | 0.480 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.196556e-01 | 0.922 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 1.199809e-01 | 0.921 | 1 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.329699e-01 | 0.876 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 1.946171e-01 | 0.711 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 2.967327e-01 | 0.528 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 3.140520e-01 | 0.503 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 3.302119e-01 | 0.481 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 2.238743e-01 | 0.650 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 2.191187e-01 | 0.659 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.836428e-01 | 0.547 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 2.608219e-01 | 0.584 | 1 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 2.107235e-01 | 0.676 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 2.107235e-01 | 0.676 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.472147e-01 | 0.607 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 1.428249e-01 | 0.845 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 3.152196e-01 | 0.501 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 3.152196e-01 | 0.501 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 3.152196e-01 | 0.501 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 3.152196e-01 | 0.501 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.927698e-01 | 0.715 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.376339e-01 | 0.861 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 3.468852e-01 | 0.460 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 1.711293e-01 | 0.767 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.320025e-01 | 0.879 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 2.619322e-01 | 0.582 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 1.946171e-01 | 0.711 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 2.188349e-01 | 0.660 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 2.967327e-01 | 0.528 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 3.140520e-01 | 0.503 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 3.167331e-01 | 0.499 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.799288e-01 | 0.553 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.922914e-01 | 0.716 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 3.446729e-01 | 0.463 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 2.978632e-01 | 0.526 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 1.158959e-01 | 0.936 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.279072e-01 | 0.893 | 1 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.445229e-01 | 0.612 | 1 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 2.967327e-01 | 0.528 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 1.758431e-01 | 0.755 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.283517e-01 | 0.892 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 2.338631e-01 | 0.631 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.238743e-01 | 0.650 | 1 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 1.159966e-01 | 0.936 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 1.159966e-01 | 0.936 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 1.397380e-01 | 0.855 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 3.140520e-01 | 0.503 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.520444e-01 | 0.818 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 2.439570e-01 | 0.613 | 1 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 1.711293e-01 | 0.767 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.960145e-01 | 0.708 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 1.758431e-01 | 0.755 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.827716e-01 | 0.738 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 2.042526e-01 | 0.690 | 1 | 1 |
| rRNA processing | R-HSA-72312 | 3.096490e-01 | 0.509 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.472147e-01 | 0.607 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 2.271618e-01 | 0.644 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 2.271618e-01 | 0.644 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 2.445229e-01 | 0.612 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.667185e-01 | 0.778 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.815394e-01 | 0.550 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.262120e-01 | 0.899 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 3.108963e-01 | 0.507 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 1.158959e-01 | 0.936 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.421553e-01 | 0.847 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 2.066450e-01 | 0.685 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.140007e-01 | 0.670 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.381508e-01 | 0.623 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.758431e-01 | 0.755 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 3.287365e-01 | 0.483 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 1.946401e-01 | 0.711 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 2.344295e-01 | 0.630 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.158959e-01 | 0.936 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.455627e-01 | 0.461 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.737519e-01 | 0.760 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 1.298991e-01 | 0.886 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 2.200648e-01 | 0.657 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.167895e-01 | 0.933 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 2.107235e-01 | 0.676 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 1.428249e-01 | 0.845 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 2.820208e-01 | 0.550 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 1.758431e-01 | 0.755 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 3.152196e-01 | 0.501 | 1 | 1 |
| Hydrolysis of LPE | R-HSA-1483152 | 3.468852e-01 | 0.460 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 2.271618e-01 | 0.644 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 1.238372e-01 | 0.907 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 1.238372e-01 | 0.907 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 1.359618e-01 | 0.867 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.657734e-01 | 0.780 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 2.348779e-01 | 0.629 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.677946e-01 | 0.775 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 2.272423e-01 | 0.644 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 2.851855e-01 | 0.545 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.035388e-01 | 0.518 | 0 | 0 |
| Immune System | R-HSA-168256 | 3.022261e-01 | 0.520 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.209851e-01 | 0.917 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 2.633809e-01 | 0.579 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 3.327479e-01 | 0.478 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 2.824713e-01 | 0.549 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.428249e-01 | 0.845 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 3.468852e-01 | 0.460 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.549219e-01 | 0.810 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 3.199237e-01 | 0.495 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.964616e-01 | 0.528 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.282958e-01 | 0.642 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.949492e-01 | 0.710 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 3.108963e-01 | 0.507 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.946171e-01 | 0.711 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.239313e-01 | 0.907 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 2.394030e-01 | 0.621 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.594332e-01 | 0.797 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.812510e-01 | 0.742 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.633508e-01 | 0.579 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.403828e-01 | 0.853 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 2.793480e-01 | 0.554 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 1.159966e-01 | 0.936 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 3.253319e-01 | 0.488 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 3.045379e-01 | 0.516 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 2.472147e-01 | 0.607 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 1.268681e-01 | 0.897 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 1.268681e-01 | 0.897 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 1.428249e-01 | 0.845 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.591733e-01 | 0.798 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 1.758431e-01 | 0.755 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 1.758431e-01 | 0.755 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 3.152196e-01 | 0.501 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 3.152196e-01 | 0.501 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 3.152196e-01 | 0.501 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 3.152196e-01 | 0.501 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 1.927698e-01 | 0.715 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 3.468852e-01 | 0.460 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 2.271618e-01 | 0.644 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 2.619322e-01 | 0.582 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.066450e-01 | 0.685 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.681731e-01 | 0.774 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 2.815394e-01 | 0.550 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.800976e-01 | 0.744 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 1.298991e-01 | 0.886 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 2.140007e-01 | 0.670 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.167132e-01 | 0.933 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.330073e-01 | 0.633 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 3.292603e-01 | 0.482 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.239700e-01 | 0.907 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.239700e-01 | 0.907 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.163112e-01 | 0.934 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 1.758431e-01 | 0.755 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.270181e-01 | 0.896 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.484764e-01 | 0.828 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 3.041548e-01 | 0.517 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 2.338631e-01 | 0.631 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 2.820208e-01 | 0.550 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 2.820208e-01 | 0.550 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.758431e-01 | 0.755 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 1.597112e-01 | 0.797 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.758629e-01 | 0.755 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 3.167331e-01 | 0.499 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.679866e-01 | 0.572 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 2.897848e-01 | 0.538 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.784019e-01 | 0.749 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.736286e-01 | 0.760 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 3.071041e-01 | 0.513 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 1.711293e-01 | 0.767 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 1.385957e-01 | 0.858 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.268681e-01 | 0.897 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 2.098942e-01 | 0.678 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.892202e-01 | 0.723 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.428249e-01 | 0.845 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 2.098942e-01 | 0.678 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.731633e-01 | 0.762 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 2.820208e-01 | 0.550 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 2.820208e-01 | 0.550 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 1.239700e-01 | 0.907 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.781087e-01 | 0.749 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.967327e-01 | 0.528 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 2.870141e-01 | 0.542 | 0 | 0 |
| Extrinsic Pathway of Fibrin Clot Formation | R-HSA-140834 | 2.472147e-01 | 0.607 | 0 | 0 |
| Defective factor VIII causes hemophilia A | R-HSA-9662001 | 3.468852e-01 | 0.460 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 2.271618e-01 | 0.644 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.892202e-01 | 0.723 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 1.581398e-01 | 0.801 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 3.133296e-01 | 0.504 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 2.445229e-01 | 0.612 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 2.967327e-01 | 0.528 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 3.384833e-01 | 0.470 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 2.330073e-01 | 0.633 | 0 | 0 |
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | R-HSA-159763 | 3.468852e-01 | 0.460 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.679866e-01 | 0.572 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 1.631889e-01 | 0.787 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.010682e-01 | 0.697 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 3.149719e-01 | 0.502 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 3.483730e-01 | 0.458 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 3.483730e-01 | 0.458 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 3.483730e-01 | 0.458 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 3.483730e-01 | 0.458 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 3.483730e-01 | 0.458 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 3.483730e-01 | 0.458 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 3.485440e-01 | 0.458 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.535609e-01 | 0.452 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 3.535609e-01 | 0.452 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.541096e-01 | 0.451 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 3.591663e-01 | 0.445 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 3.591663e-01 | 0.445 | 1 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 3.591663e-01 | 0.445 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.591663e-01 | 0.445 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.615861e-01 | 0.442 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 3.653214e-01 | 0.437 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 3.653214e-01 | 0.437 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 3.653214e-01 | 0.437 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 3.653214e-01 | 0.437 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 3.697846e-01 | 0.432 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.701909e-01 | 0.432 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.711099e-01 | 0.430 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.711099e-01 | 0.430 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 3.711099e-01 | 0.430 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 3.727665e-01 | 0.429 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 3.770884e-01 | 0.424 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.770884e-01 | 0.424 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 3.770884e-01 | 0.424 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 3.770884e-01 | 0.424 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 3.770884e-01 | 0.424 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.770884e-01 | 0.424 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 3.770884e-01 | 0.424 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 3.770884e-01 | 0.424 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 3.770884e-01 | 0.424 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 3.770884e-01 | 0.424 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 3.770884e-01 | 0.424 | 0 | 0 |
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | R-HSA-159782 | 3.770884e-01 | 0.424 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 3.800636e-01 | 0.420 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 3.805575e-01 | 0.420 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 3.820973e-01 | 0.418 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 3.820973e-01 | 0.418 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 3.820973e-01 | 0.418 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 3.820973e-01 | 0.418 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 3.820973e-01 | 0.418 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 3.820973e-01 | 0.418 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 3.820973e-01 | 0.418 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 3.820973e-01 | 0.418 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 3.838173e-01 | 0.416 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 3.838173e-01 | 0.416 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 3.838173e-01 | 0.416 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 3.847845e-01 | 0.415 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 3.847845e-01 | 0.415 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 3.871408e-01 | 0.412 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 3.876282e-01 | 0.412 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 3.909786e-01 | 0.408 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 3.951779e-01 | 0.403 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 3.951779e-01 | 0.403 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 3.952586e-01 | 0.403 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 3.964650e-01 | 0.402 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.964650e-01 | 0.402 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 3.964650e-01 | 0.402 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 3.986805e-01 | 0.399 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 3.986805e-01 | 0.399 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 3.986805e-01 | 0.399 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.986805e-01 | 0.399 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 3.986805e-01 | 0.399 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 3.986805e-01 | 0.399 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 3.986805e-01 | 0.399 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 4.015396e-01 | 0.396 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 4.017964e-01 | 0.396 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 4.032929e-01 | 0.394 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.035030e-01 | 0.394 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 4.058967e-01 | 0.392 | 0 | 0 |
| RSK activation | R-HSA-444257 | 4.058967e-01 | 0.392 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 4.058967e-01 | 0.392 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 4.058967e-01 | 0.392 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 4.058967e-01 | 0.392 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 4.058967e-01 | 0.392 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 4.058967e-01 | 0.392 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 4.058967e-01 | 0.392 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 4.058967e-01 | 0.392 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 4.058967e-01 | 0.392 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 4.058967e-01 | 0.392 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 4.058967e-01 | 0.392 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 4.058967e-01 | 0.392 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 4.090419e-01 | 0.388 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 4.090419e-01 | 0.388 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 4.090419e-01 | 0.388 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.090419e-01 | 0.388 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 4.090602e-01 | 0.388 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 4.150529e-01 | 0.382 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 4.150529e-01 | 0.382 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 4.150529e-01 | 0.382 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 4.150529e-01 | 0.382 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 4.150529e-01 | 0.382 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 4.215379e-01 | 0.375 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 4.225553e-01 | 0.374 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 4.225553e-01 | 0.374 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 4.225553e-01 | 0.374 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.225553e-01 | 0.374 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 4.284158e-01 | 0.368 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 4.311987e-01 | 0.365 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 4.311987e-01 | 0.365 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 4.311987e-01 | 0.365 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 4.311987e-01 | 0.365 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 4.311987e-01 | 0.365 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 4.311987e-01 | 0.365 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 4.311987e-01 | 0.365 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 4.311987e-01 | 0.365 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 4.311987e-01 | 0.365 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 4.311987e-01 | 0.365 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 4.333742e-01 | 0.363 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 4.333742e-01 | 0.363 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 4.333742e-01 | 0.363 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 4.333742e-01 | 0.363 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 4.333742e-01 | 0.363 | 0 | 0 |
| Enzymatic degradation of Dopamine by monoamine oxidase | R-HSA-379398 | 4.333742e-01 | 0.363 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 4.333742e-01 | 0.363 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 4.333742e-01 | 0.363 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 4.333742e-01 | 0.363 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 4.339433e-01 | 0.363 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.339433e-01 | 0.363 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.409415e-01 | 0.356 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.409415e-01 | 0.356 | 0 | 0 |
| Disease | R-HSA-1643685 | 4.414362e-01 | 0.355 | 1 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 4.433864e-01 | 0.353 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 4.449379e-01 | 0.352 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 4.462490e-01 | 0.350 | 0 | 0 |
| Methylation | R-HSA-156581 | 4.462490e-01 | 0.350 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 4.462490e-01 | 0.350 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 4.462490e-01 | 0.350 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 4.462490e-01 | 0.350 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 4.466571e-01 | 0.350 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 4.471036e-01 | 0.350 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 4.471036e-01 | 0.350 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 4.491909e-01 | 0.348 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 4.494674e-01 | 0.347 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 4.537176e-01 | 0.343 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 4.555875e-01 | 0.341 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 4.555875e-01 | 0.341 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 4.571769e-01 | 0.340 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 4.584466e-01 | 0.339 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 4.584466e-01 | 0.339 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 4.584466e-01 | 0.339 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 4.584466e-01 | 0.339 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 4.584466e-01 | 0.339 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.584466e-01 | 0.339 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 4.595825e-01 | 0.338 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 4.595825e-01 | 0.338 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 4.595825e-01 | 0.338 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 4.595825e-01 | 0.338 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 4.595825e-01 | 0.338 | 0 | 0 |
| Enzymatic degradation of dopamine by COMT | R-HSA-379397 | 4.595825e-01 | 0.338 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.595825e-01 | 0.338 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 4.595825e-01 | 0.338 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 4.613603e-01 | 0.336 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 4.627557e-01 | 0.335 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 4.627557e-01 | 0.335 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 4.627557e-01 | 0.335 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 4.627557e-01 | 0.335 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 4.627557e-01 | 0.335 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 4.635977e-01 | 0.334 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 4.635977e-01 | 0.334 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 4.705283e-01 | 0.327 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 4.705283e-01 | 0.327 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.705283e-01 | 0.327 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 4.744321e-01 | 0.324 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 4.762985e-01 | 0.322 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 4.776581e-01 | 0.321 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 4.779807e-01 | 0.321 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 4.781441e-01 | 0.320 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 4.781441e-01 | 0.320 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.824867e-01 | 0.317 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 4.843077e-01 | 0.315 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.843077e-01 | 0.315 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 4.845801e-01 | 0.315 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 4.845801e-01 | 0.315 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 4.845801e-01 | 0.315 | 0 | 0 |
| Conjugation of benzoate with glycine | R-HSA-177135 | 4.845801e-01 | 0.315 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 4.845801e-01 | 0.315 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.845801e-01 | 0.315 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 4.845801e-01 | 0.315 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 4.845801e-01 | 0.315 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 4.845801e-01 | 0.315 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 4.845801e-01 | 0.315 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 4.932598e-01 | 0.307 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 4.932598e-01 | 0.307 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 4.932598e-01 | 0.307 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 4.941245e-01 | 0.306 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 5.018209e-01 | 0.299 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 5.029532e-01 | 0.298 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 5.043152e-01 | 0.297 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 5.060075e-01 | 0.296 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 5.060075e-01 | 0.296 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 5.060075e-01 | 0.296 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 5.080952e-01 | 0.294 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 5.080952e-01 | 0.294 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 5.084229e-01 | 0.294 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 5.084229e-01 | 0.294 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 5.084229e-01 | 0.294 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 5.084229e-01 | 0.294 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 5.084229e-01 | 0.294 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 5.084229e-01 | 0.294 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 5.084229e-01 | 0.294 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.084229e-01 | 0.294 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 5.084229e-01 | 0.294 | 0 | 0 |
| Uptake of dietary cobalamins into enterocytes | R-HSA-9758881 | 5.084229e-01 | 0.294 | 0 | 0 |
| Gamma-carboxylation of protein precursors | R-HSA-159740 | 5.084229e-01 | 0.294 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.141896e-01 | 0.289 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.141896e-01 | 0.289 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 5.141896e-01 | 0.289 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 5.155237e-01 | 0.288 | 1 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 5.177089e-01 | 0.286 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 5.177089e-01 | 0.286 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 5.226438e-01 | 0.282 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 5.226438e-01 | 0.282 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 5.226438e-01 | 0.282 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 5.226438e-01 | 0.282 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 5.272777e-01 | 0.278 | 1 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 5.289610e-01 | 0.277 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 5.289610e-01 | 0.277 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 5.311641e-01 | 0.275 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 5.311641e-01 | 0.275 | 0 | 0 |
| Conjugation of salicylate with glycine | R-HSA-177128 | 5.311641e-01 | 0.275 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 5.311641e-01 | 0.275 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 5.311641e-01 | 0.275 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 5.311641e-01 | 0.275 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 5.311641e-01 | 0.275 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 5.311641e-01 | 0.275 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 5.311641e-01 | 0.275 | 0 | 0 |
| Gamma-carboxylation, transport, and amino-terminal cleavage of proteins | R-HSA-159854 | 5.311641e-01 | 0.275 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 5.311641e-01 | 0.275 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 5.311641e-01 | 0.275 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 5.369004e-01 | 0.270 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 5.369004e-01 | 0.270 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 5.376258e-01 | 0.270 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 5.383714e-01 | 0.269 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 5.402124e-01 | 0.267 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 5.402124e-01 | 0.267 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 5.411610e-01 | 0.267 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.432478e-01 | 0.265 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 5.508610e-01 | 0.259 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 5.513076e-01 | 0.259 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 5.527338e-01 | 0.257 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 5.527338e-01 | 0.257 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 5.528545e-01 | 0.257 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.528545e-01 | 0.257 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 5.528545e-01 | 0.257 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 5.528545e-01 | 0.257 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 5.528545e-01 | 0.257 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 5.528545e-01 | 0.257 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 5.528545e-01 | 0.257 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.528545e-01 | 0.257 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 5.528545e-01 | 0.257 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 5.545464e-01 | 0.256 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 5.621144e-01 | 0.250 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 5.621144e-01 | 0.250 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 5.628896e-01 | 0.250 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 5.641044e-01 | 0.249 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 5.645223e-01 | 0.248 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 5.645223e-01 | 0.248 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 5.645966e-01 | 0.248 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 5.671206e-01 | 0.246 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 5.711533e-01 | 0.243 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 5.711533e-01 | 0.243 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 5.713868e-01 | 0.243 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 5.735428e-01 | 0.241 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 5.735428e-01 | 0.241 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 5.735428e-01 | 0.241 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 5.735428e-01 | 0.241 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 5.735428e-01 | 0.241 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 5.778822e-01 | 0.238 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 5.778822e-01 | 0.238 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 5.778822e-01 | 0.238 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 5.778822e-01 | 0.238 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 5.778822e-01 | 0.238 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 5.778822e-01 | 0.238 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 5.790911e-01 | 0.237 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 5.790911e-01 | 0.237 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 5.793352e-01 | 0.237 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 5.805483e-01 | 0.236 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 5.836201e-01 | 0.234 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 5.836201e-01 | 0.234 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 5.874334e-01 | 0.231 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 5.874334e-01 | 0.231 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 5.874334e-01 | 0.231 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 5.909393e-01 | 0.228 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 5.909393e-01 | 0.228 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 5.932750e-01 | 0.227 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 5.932750e-01 | 0.227 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 5.932750e-01 | 0.227 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 5.932750e-01 | 0.227 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 5.932750e-01 | 0.227 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 5.932750e-01 | 0.227 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 5.932750e-01 | 0.227 | 0 | 0 |
| Protein repair | R-HSA-5676934 | 5.932750e-01 | 0.227 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 5.932750e-01 | 0.227 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 5.932750e-01 | 0.227 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 5.932750e-01 | 0.227 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 5.932750e-01 | 0.227 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 5.932750e-01 | 0.227 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 5.932750e-01 | 0.227 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 5.932750e-01 | 0.227 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 5.985294e-01 | 0.223 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 6.036931e-01 | 0.219 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 6.036931e-01 | 0.219 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 6.036931e-01 | 0.219 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 6.036931e-01 | 0.219 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 6.036931e-01 | 0.219 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 6.036931e-01 | 0.219 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 6.047008e-01 | 0.218 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 6.054122e-01 | 0.218 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 6.073447e-01 | 0.217 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 6.112072e-01 | 0.214 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 6.120953e-01 | 0.213 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 6.120953e-01 | 0.213 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 6.120953e-01 | 0.213 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.120953e-01 | 0.213 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 6.120953e-01 | 0.213 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 6.120953e-01 | 0.213 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 6.120953e-01 | 0.213 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 6.120953e-01 | 0.213 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 6.120953e-01 | 0.213 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 6.130827e-01 | 0.212 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 6.130827e-01 | 0.212 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 6.130827e-01 | 0.212 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 6.144131e-01 | 0.212 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 6.160408e-01 | 0.210 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 6.161437e-01 | 0.210 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 6.161437e-01 | 0.210 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 6.161437e-01 | 0.210 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 6.161437e-01 | 0.210 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.189527e-01 | 0.208 | 0 | 0 |
| Kinesins | R-HSA-983189 | 6.243300e-01 | 0.205 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 6.282918e-01 | 0.202 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 6.282918e-01 | 0.202 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 6.293924e-01 | 0.201 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 6.300459e-01 | 0.201 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 6.300459e-01 | 0.201 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 6.300459e-01 | 0.201 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 6.300459e-01 | 0.201 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 6.300459e-01 | 0.201 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 6.300459e-01 | 0.201 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 6.300459e-01 | 0.201 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 6.300459e-01 | 0.201 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 6.300459e-01 | 0.201 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 6.300459e-01 | 0.201 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 6.330687e-01 | 0.199 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 6.340707e-01 | 0.198 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 6.340707e-01 | 0.198 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 6.341666e-01 | 0.198 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 6.401387e-01 | 0.194 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 6.401387e-01 | 0.194 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 6.401387e-01 | 0.194 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 6.401387e-01 | 0.194 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 6.401387e-01 | 0.194 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 6.401387e-01 | 0.194 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 6.416325e-01 | 0.193 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 6.416325e-01 | 0.193 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 6.471669e-01 | 0.189 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.471669e-01 | 0.189 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 6.471669e-01 | 0.189 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 6.471669e-01 | 0.189 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 6.471669e-01 | 0.189 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 6.471669e-01 | 0.189 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.471669e-01 | 0.189 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 6.471669e-01 | 0.189 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 6.496023e-01 | 0.187 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 6.516863e-01 | 0.186 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 6.516863e-01 | 0.186 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 6.516863e-01 | 0.186 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 6.530201e-01 | 0.185 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 6.558037e-01 | 0.183 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 6.576811e-01 | 0.182 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 6.586984e-01 | 0.181 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 6.621454e-01 | 0.179 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 6.622277e-01 | 0.179 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 6.629369e-01 | 0.179 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 6.629369e-01 | 0.179 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 6.629369e-01 | 0.179 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 6.634965e-01 | 0.178 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 6.634965e-01 | 0.178 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 6.634965e-01 | 0.178 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 6.634965e-01 | 0.178 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 6.634965e-01 | 0.178 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 6.654557e-01 | 0.177 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.705328e-01 | 0.174 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.705328e-01 | 0.174 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 6.734588e-01 | 0.172 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 6.734588e-01 | 0.172 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 6.738932e-01 | 0.171 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 6.738932e-01 | 0.171 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 6.738932e-01 | 0.171 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 6.738932e-01 | 0.171 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 6.738932e-01 | 0.171 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 6.738932e-01 | 0.171 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.764203e-01 | 0.170 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.775131e-01 | 0.169 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 6.790713e-01 | 0.168 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 6.790713e-01 | 0.168 | 0 | 0 |
| Amino Acid conjugation | R-HSA-156587 | 6.790713e-01 | 0.168 | 0 | 0 |
| Conjugation of carboxylic acids | R-HSA-159424 | 6.790713e-01 | 0.168 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 6.790713e-01 | 0.168 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 6.790713e-01 | 0.168 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 6.790713e-01 | 0.168 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 6.790713e-01 | 0.168 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 6.790713e-01 | 0.168 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 6.790713e-01 | 0.168 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 6.790713e-01 | 0.168 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 6.790713e-01 | 0.168 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 6.817239e-01 | 0.166 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 6.845585e-01 | 0.165 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 6.845585e-01 | 0.165 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 6.874600e-01 | 0.163 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 6.874600e-01 | 0.163 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 6.880031e-01 | 0.162 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 6.887805e-01 | 0.162 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 6.889990e-01 | 0.162 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 6.933371e-01 | 0.159 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 6.939261e-01 | 0.159 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 6.939261e-01 | 0.159 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 6.939261e-01 | 0.159 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 6.939261e-01 | 0.159 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 6.939261e-01 | 0.159 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 6.939261e-01 | 0.159 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 6.939261e-01 | 0.159 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 6.939261e-01 | 0.159 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 6.948094e-01 | 0.158 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 6.949361e-01 | 0.158 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 6.961686e-01 | 0.157 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 6.972757e-01 | 0.157 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 6.978572e-01 | 0.156 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 6.978572e-01 | 0.156 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 6.982610e-01 | 0.156 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.009081e-01 | 0.154 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 7.034824e-01 | 0.153 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 7.044385e-01 | 0.152 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 7.046728e-01 | 0.152 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 7.050298e-01 | 0.152 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 7.050298e-01 | 0.152 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 7.050298e-01 | 0.152 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 7.055940e-01 | 0.151 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 7.080942e-01 | 0.150 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 7.080942e-01 | 0.150 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 7.080942e-01 | 0.150 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 7.080942e-01 | 0.150 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.080942e-01 | 0.150 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 7.080942e-01 | 0.150 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 7.080942e-01 | 0.150 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 7.082420e-01 | 0.150 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 7.137363e-01 | 0.146 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 7.148437e-01 | 0.146 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 7.148437e-01 | 0.146 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 7.148437e-01 | 0.146 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 7.148437e-01 | 0.146 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 7.148437e-01 | 0.146 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 7.211508e-01 | 0.142 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 7.216073e-01 | 0.142 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 7.216073e-01 | 0.142 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 7.216073e-01 | 0.142 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 7.217037e-01 | 0.142 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 7.217037e-01 | 0.142 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 7.217037e-01 | 0.142 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 7.243820e-01 | 0.140 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 7.307529e-01 | 0.136 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 7.336492e-01 | 0.135 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 7.336492e-01 | 0.135 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 7.344956e-01 | 0.134 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 7.344956e-01 | 0.134 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 7.344956e-01 | 0.134 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 7.344956e-01 | 0.134 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 7.350248e-01 | 0.134 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 7.357637e-01 | 0.133 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 7.381356e-01 | 0.132 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 7.388333e-01 | 0.131 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 7.412826e-01 | 0.130 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 7.418162e-01 | 0.130 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 7.426499e-01 | 0.129 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 7.426499e-01 | 0.129 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 7.467880e-01 | 0.127 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 7.467880e-01 | 0.127 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 7.467880e-01 | 0.127 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 7.467880e-01 | 0.127 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 7.467880e-01 | 0.127 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 7.467880e-01 | 0.127 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 7.513890e-01 | 0.124 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 7.513890e-01 | 0.124 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 7.585119e-01 | 0.120 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 7.585119e-01 | 0.120 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 7.585119e-01 | 0.120 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 7.585119e-01 | 0.120 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 7.589634e-01 | 0.120 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 7.598714e-01 | 0.119 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 7.635858e-01 | 0.117 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 7.681020e-01 | 0.115 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 7.696938e-01 | 0.114 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 7.696938e-01 | 0.114 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 7.696938e-01 | 0.114 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 7.696938e-01 | 0.114 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.696938e-01 | 0.114 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 7.696938e-01 | 0.114 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 7.696938e-01 | 0.114 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 7.760804e-01 | 0.110 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 7.793175e-01 | 0.108 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 7.803585e-01 | 0.108 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 7.803585e-01 | 0.108 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 7.803585e-01 | 0.108 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 7.803585e-01 | 0.108 | 0 | 0 |
| Attachment of bacteria to epithelial cells | R-HSA-9638630 | 7.803585e-01 | 0.108 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 7.803585e-01 | 0.108 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 7.838286e-01 | 0.106 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 7.857801e-01 | 0.105 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 7.905300e-01 | 0.102 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 7.913350e-01 | 0.102 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 7.926401e-01 | 0.101 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 7.986105e-01 | 0.098 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 7.986105e-01 | 0.098 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 7.986105e-01 | 0.098 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 8.002310e-01 | 0.097 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 8.002310e-01 | 0.097 | 1 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 8.002310e-01 | 0.097 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.011044e-01 | 0.096 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 8.042324e-01 | 0.095 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 8.094833e-01 | 0.092 | 1 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.094833e-01 | 0.092 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 8.183077e-01 | 0.087 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.183077e-01 | 0.087 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.183077e-01 | 0.087 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.183077e-01 | 0.087 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 8.187585e-01 | 0.087 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 8.191042e-01 | 0.087 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 8.191042e-01 | 0.087 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 8.191042e-01 | 0.087 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 8.230285e-01 | 0.085 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 8.242237e-01 | 0.084 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 8.255087e-01 | 0.083 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 8.267167e-01 | 0.083 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 8.267238e-01 | 0.083 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.267238e-01 | 0.083 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 8.267238e-01 | 0.083 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 8.267238e-01 | 0.083 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 8.267238e-01 | 0.083 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 8.317086e-01 | 0.080 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 8.317086e-01 | 0.080 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 8.317086e-01 | 0.080 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 8.346473e-01 | 0.078 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 8.347506e-01 | 0.078 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 8.347506e-01 | 0.078 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 8.376512e-01 | 0.077 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 8.385020e-01 | 0.076 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.385020e-01 | 0.076 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 8.424060e-01 | 0.074 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 8.424060e-01 | 0.074 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 8.424060e-01 | 0.074 | 1 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 8.424060e-01 | 0.074 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 8.424060e-01 | 0.074 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 8.424060e-01 | 0.074 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 8.424060e-01 | 0.074 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 8.435155e-01 | 0.074 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 8.452652e-01 | 0.073 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 8.469954e-01 | 0.072 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 8.497072e-01 | 0.071 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 8.497072e-01 | 0.071 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 8.497072e-01 | 0.071 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 8.517266e-01 | 0.070 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 8.566706e-01 | 0.067 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.566706e-01 | 0.067 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 8.566706e-01 | 0.067 | 1 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 8.566706e-01 | 0.067 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 8.566706e-01 | 0.067 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 8.566706e-01 | 0.067 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 8.566706e-01 | 0.067 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.594124e-01 | 0.066 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 8.598197e-01 | 0.066 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 8.603577e-01 | 0.065 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.607934e-01 | 0.065 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 8.633117e-01 | 0.064 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 8.633117e-01 | 0.064 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 8.635286e-01 | 0.064 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 8.735136e-01 | 0.059 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 8.756862e-01 | 0.058 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.756862e-01 | 0.058 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.756862e-01 | 0.058 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 8.775151e-01 | 0.057 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.808212e-01 | 0.055 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 8.814038e-01 | 0.055 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 8.814473e-01 | 0.055 | 0 | 0 |
| Biofilm formation | R-HSA-9931953 | 8.814473e-01 | 0.055 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 8.814473e-01 | 0.055 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 8.835731e-01 | 0.054 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 8.835731e-01 | 0.054 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 8.835731e-01 | 0.054 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 8.878533e-01 | 0.052 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 8.878533e-01 | 0.052 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 8.879985e-01 | 0.052 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 8.879985e-01 | 0.052 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 8.919872e-01 | 0.050 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 8.919872e-01 | 0.050 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 8.921819e-01 | 0.050 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 8.921819e-01 | 0.050 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 8.921819e-01 | 0.050 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 8.959792e-01 | 0.048 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 8.959792e-01 | 0.048 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 8.974729e-01 | 0.047 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 8.974729e-01 | 0.047 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 8.974729e-01 | 0.047 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 8.992433e-01 | 0.046 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.019456e-01 | 0.045 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.019456e-01 | 0.045 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.035545e-01 | 0.044 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 9.056756e-01 | 0.043 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 9.064912e-01 | 0.043 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 9.064912e-01 | 0.043 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.064912e-01 | 0.043 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.108263e-01 | 0.041 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.117343e-01 | 0.040 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 9.139567e-01 | 0.039 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 9.139567e-01 | 0.039 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 9.149606e-01 | 0.039 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.149606e-01 | 0.039 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.189036e-01 | 0.037 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.189950e-01 | 0.037 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.193706e-01 | 0.037 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 9.201614e-01 | 0.036 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.226639e-01 | 0.035 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.226639e-01 | 0.035 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 9.226639e-01 | 0.035 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.228029e-01 | 0.035 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.232992e-01 | 0.035 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.251746e-01 | 0.034 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 9.262501e-01 | 0.033 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.280022e-01 | 0.032 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.289872e-01 | 0.032 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.289874e-01 | 0.032 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 9.296702e-01 | 0.032 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.296702e-01 | 0.032 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 9.308343e-01 | 0.031 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.308343e-01 | 0.031 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.315482e-01 | 0.031 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 9.342755e-01 | 0.030 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 9.349922e-01 | 0.029 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.379192e-01 | 0.028 | 0 | 0 |
| Translation | R-HSA-72766 | 9.389379e-01 | 0.027 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 9.390090e-01 | 0.027 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.390090e-01 | 0.027 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 9.418381e-01 | 0.026 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 9.418381e-01 | 0.026 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.432114e-01 | 0.025 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 9.445362e-01 | 0.025 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.445362e-01 | 0.025 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 9.471092e-01 | 0.024 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.471092e-01 | 0.024 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.488286e-01 | 0.023 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.488286e-01 | 0.023 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 9.495630e-01 | 0.022 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 9.519031e-01 | 0.021 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.541348e-01 | 0.020 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.541348e-01 | 0.020 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.546343e-01 | 0.020 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.555678e-01 | 0.020 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.562631e-01 | 0.019 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.580251e-01 | 0.019 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.582927e-01 | 0.019 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.582927e-01 | 0.019 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.585168e-01 | 0.018 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.596156e-01 | 0.018 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 9.602283e-01 | 0.018 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.602283e-01 | 0.018 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.602283e-01 | 0.018 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.602283e-01 | 0.018 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.620741e-01 | 0.017 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.626934e-01 | 0.017 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 9.638344e-01 | 0.016 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.638344e-01 | 0.016 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.653671e-01 | 0.015 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 9.676759e-01 | 0.014 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.694196e-01 | 0.013 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.700965e-01 | 0.013 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.714848e-01 | 0.013 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.714848e-01 | 0.013 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.733500e-01 | 0.012 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.752754e-01 | 0.011 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.756082e-01 | 0.011 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.764236e-01 | 0.010 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.764236e-01 | 0.010 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.764236e-01 | 0.010 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 9.775186e-01 | 0.010 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.775186e-01 | 0.010 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.822769e-01 | 0.008 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.831003e-01 | 0.007 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.831003e-01 | 0.007 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 9.846342e-01 | 0.007 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.875206e-01 | 0.005 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.889878e-01 | 0.005 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 9.889878e-01 | 0.005 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.894997e-01 | 0.005 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.896769e-01 | 0.005 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.907594e-01 | 0.004 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.916125e-01 | 0.004 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 9.917241e-01 | 0.004 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.920438e-01 | 0.003 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.921090e-01 | 0.003 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.924760e-01 | 0.003 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.928259e-01 | 0.003 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.932963e-01 | 0.003 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.937812e-01 | 0.003 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.937812e-01 | 0.003 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 9.939420e-01 | 0.003 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.946094e-01 | 0.002 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.947733e-01 | 0.002 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.961530e-01 | 0.002 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.962224e-01 | 0.002 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.969439e-01 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.969575e-01 | 0.001 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.973172e-01 | 0.001 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.974301e-01 | 0.001 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.975233e-01 | 0.001 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.976029e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.978210e-01 | 0.001 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.982605e-01 | 0.001 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.983635e-01 | 0.001 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.983973e-01 | 0.001 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.985163e-01 | 0.001 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.988078e-01 | 0.001 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.990771e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.991119e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.993205e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.993394e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.993702e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.996095e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.996761e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.997580e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999267e-01 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.999359e-01 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 9.999745e-01 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.999761e-01 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.999991e-01 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.999993e-01 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 9.999994e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999995e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999999e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.000000e+00 | 0.000 | 1 | 1 |
| ARMS-mediated activation | R-HSA-170984 | 1.000000e+00 | 0.000 | 1 | 1 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 1.000000e+00 | 0.000 | 1 | 1 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.000000e+00 | 0.000 | 1 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.000000e+00 | 0.000 | 1 | 1 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.000000e+00 | 0.000 | 1 | 1 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.609935e-07 | 6.583 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 6.568441e-07 | 6.183 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.780553e-06 | 5.556 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 3.566368e-06 | 5.448 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 8.944359e-06 | 5.048 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 8.545012e-06 | 5.068 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 9.305441e-06 | 5.031 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.178877e-05 | 4.929 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.224331e-05 | 4.653 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 8.159188e-05 | 4.088 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 9.281720e-05 | 4.032 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.228908e-04 | 3.910 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.531874e-04 | 3.815 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 1.642021e-04 | 3.785 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 2.031005e-04 | 3.692 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.988094e-04 | 3.525 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 3.695251e-04 | 3.432 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 4.025259e-04 | 3.395 | 0 | 0 |
| Kinesins | R-HSA-983189 | 5.166674e-04 | 3.287 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 5.804560e-04 | 3.236 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 6.255804e-04 | 3.204 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 6.952505e-04 | 3.158 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 8.100028e-04 | 3.092 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 8.415691e-04 | 3.075 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 9.197447e-04 | 3.036 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 8.910858e-04 | 3.050 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 9.772727e-04 | 3.010 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.038481e-03 | 2.984 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.163364e-03 | 2.934 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 1.322778e-03 | 2.879 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 1.322778e-03 | 2.879 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 1.519101e-03 | 2.818 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.706707e-03 | 2.768 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 2.036373e-03 | 2.691 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 2.167681e-03 | 2.664 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.462863e-03 | 2.609 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 2.968043e-03 | 2.528 | 1 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.398036e-03 | 2.469 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.398036e-03 | 2.469 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 3.264184e-03 | 2.486 | 0 | 0 |
| PKA activation | R-HSA-163615 | 3.738044e-03 | 2.427 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 3.738044e-03 | 2.427 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 3.523228e-03 | 2.453 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 4.607003e-03 | 2.337 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 4.990780e-03 | 2.302 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 5.044087e-03 | 2.297 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 5.426913e-03 | 2.265 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 5.399736e-03 | 2.268 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 5.726314e-03 | 2.242 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 5.565105e-03 | 2.255 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 5.565105e-03 | 2.255 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 5.610088e-03 | 2.251 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 5.610088e-03 | 2.251 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 7.585449e-03 | 2.120 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 8.051238e-03 | 2.094 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 7.880965e-03 | 2.103 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 8.441024e-03 | 2.074 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 9.651017e-03 | 2.015 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 1.047684e-02 | 1.980 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.004267e-02 | 1.998 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.061012e-02 | 1.974 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 1.119596e-02 | 1.951 | 1 | 1 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.080719e-02 | 1.966 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.080719e-02 | 1.966 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.158700e-02 | 1.936 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.273131e-02 | 1.895 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.249019e-02 | 1.903 | 1 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.284440e-02 | 1.891 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.366413e-02 | 1.864 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.369757e-02 | 1.863 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 1.414157e-02 | 1.850 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 1.420293e-02 | 1.848 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.511649e-02 | 1.821 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.554054e-02 | 1.809 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 1.573215e-02 | 1.803 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.651734e-02 | 1.782 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.599434e-02 | 1.796 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.671541e-02 | 1.777 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.673791e-02 | 1.776 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.695404e-02 | 1.771 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 1.695404e-02 | 1.771 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 1.695404e-02 | 1.771 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 1.886286e-02 | 1.724 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 1.886286e-02 | 1.724 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.810617e-02 | 1.742 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 2.043166e-02 | 1.690 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 2.043166e-02 | 1.690 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.165480e-02 | 1.664 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 2.711696e-02 | 1.567 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 2.711696e-02 | 1.567 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 2.659942e-02 | 1.575 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.613446e-02 | 1.583 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 2.613446e-02 | 1.583 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.811874e-02 | 1.551 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.766240e-02 | 1.558 | 1 | 1 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.750383e-02 | 1.561 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.659942e-02 | 1.575 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.713419e-02 | 1.566 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 2.672717e-02 | 1.573 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 2.811874e-02 | 1.551 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.750383e-02 | 1.561 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 2.766240e-02 | 1.558 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 2.939556e-02 | 1.532 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.986576e-02 | 1.525 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 2.997834e-02 | 1.523 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 3.023821e-02 | 1.519 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 3.181879e-02 | 1.497 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 3.224644e-02 | 1.492 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 3.117865e-02 | 1.506 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 3.305445e-02 | 1.481 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.350807e-02 | 1.475 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.420013e-02 | 1.466 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 3.708839e-02 | 1.431 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 3.668820e-02 | 1.435 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 3.610862e-02 | 1.442 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 3.708839e-02 | 1.431 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 3.708839e-02 | 1.431 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.635666e-02 | 1.439 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 3.704550e-02 | 1.431 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 3.610862e-02 | 1.442 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 3.753491e-02 | 1.426 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 4.135375e-02 | 1.383 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 4.135375e-02 | 1.383 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 4.087161e-02 | 1.389 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 4.087161e-02 | 1.389 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 4.087161e-02 | 1.389 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 3.881438e-02 | 1.411 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 4.087294e-02 | 1.389 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 4.038232e-02 | 1.394 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 4.135375e-02 | 1.383 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 4.087294e-02 | 1.389 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 3.802798e-02 | 1.420 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 3.933420e-02 | 1.405 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 4.167741e-02 | 1.380 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 4.167741e-02 | 1.380 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 4.167741e-02 | 1.380 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 4.416102e-02 | 1.355 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.525165e-02 | 1.344 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 4.574163e-02 | 1.340 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 4.574163e-02 | 1.340 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 4.747358e-02 | 1.324 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 4.747358e-02 | 1.324 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 5.089665e-02 | 1.293 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 5.089665e-02 | 1.293 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 4.890158e-02 | 1.311 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 5.165890e-02 | 1.287 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 5.192316e-02 | 1.285 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 5.430202e-02 | 1.265 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 5.824647e-02 | 1.235 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 5.377091e-02 | 1.269 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 5.611903e-02 | 1.251 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 5.824647e-02 | 1.235 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 5.514613e-02 | 1.258 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 5.514613e-02 | 1.258 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 5.469376e-02 | 1.262 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 5.944883e-02 | 1.226 | 1 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.447678e-02 | 1.264 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 5.513471e-02 | 1.259 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 5.547512e-02 | 1.256 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 5.641429e-02 | 1.249 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 6.048673e-02 | 1.218 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 6.057871e-02 | 1.218 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 6.131154e-02 | 1.212 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 6.229043e-02 | 1.206 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 6.502882e-02 | 1.187 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 6.502882e-02 | 1.187 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.502882e-02 | 1.187 | 1 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 6.502882e-02 | 1.187 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 6.554232e-02 | 1.183 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 6.617964e-02 | 1.179 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.010296e-01 | 0.996 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.010296e-01 | 0.996 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.010296e-01 | 0.996 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.010296e-01 | 0.996 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.010296e-01 | 0.996 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.010296e-01 | 0.996 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.010296e-01 | 0.996 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.010296e-01 | 0.996 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.010296e-01 | 0.996 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.010296e-01 | 0.996 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.010296e-01 | 0.996 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.010296e-01 | 0.996 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.010296e-01 | 0.996 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.010296e-01 | 0.996 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.010296e-01 | 0.996 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.010296e-01 | 0.996 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 6.863836e-02 | 1.163 | 0 | 0 |
| CASP5 inflammasome assembly | R-HSA-9948011 | 1.918576e-01 | 0.717 | 0 | 0 |
| MGMT-mediated DNA damage reversal | R-HSA-5657655 | 1.918576e-01 | 0.717 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.918576e-01 | 0.717 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.918576e-01 | 0.717 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.918576e-01 | 0.717 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 1.918576e-01 | 0.717 | 0 | 0 |
| Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI) | R-HSA-9036092 | 1.918576e-01 | 0.717 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.918576e-01 | 0.717 | 0 | 0 |
| Defective SLC2A10 causes arterial tortuosity syndrome (ATS) | R-HSA-5619068 | 1.918576e-01 | 0.717 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.918576e-01 | 0.717 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 1.918576e-01 | 0.717 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 1.918576e-01 | 0.717 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 1.918576e-01 | 0.717 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 1.001954e-01 | 0.999 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.001954e-01 | 0.999 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 1.001954e-01 | 0.999 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 7.278017e-02 | 1.138 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 1.348842e-01 | 0.870 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 1.348842e-01 | 0.870 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 2.735136e-01 | 0.563 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 2.735136e-01 | 0.563 | 0 | 0 |
| t(4;14) translocations of FGFR3 | R-HSA-2033515 | 2.735136e-01 | 0.563 | 0 | 0 |
| Signaling by FGFR3 fusions in cancer | R-HSA-8853334 | 2.735136e-01 | 0.563 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 2.735136e-01 | 0.563 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 2.735136e-01 | 0.563 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 2.735136e-01 | 0.563 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 2.735136e-01 | 0.563 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 2.735136e-01 | 0.563 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 2.735136e-01 | 0.563 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 2.735136e-01 | 0.563 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 9.258442e-02 | 1.033 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 9.258442e-02 | 1.033 | 1 | 1 |
| G2 Phase | R-HSA-68911 | 1.717506e-01 | 0.765 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 1.717506e-01 | 0.765 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 1.717506e-01 | 0.765 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.143361e-01 | 0.942 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.143361e-01 | 0.942 | 1 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.143361e-01 | 0.942 | 1 | 1 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 7.838330e-02 | 1.106 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 7.838330e-02 | 1.106 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 9.369656e-02 | 1.028 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 9.369656e-02 | 1.028 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 1.377954e-01 | 0.861 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 1.377954e-01 | 0.861 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 1.377954e-01 | 0.861 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 2.100012e-01 | 0.678 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 2.100012e-01 | 0.678 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 2.100012e-01 | 0.678 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 2.100012e-01 | 0.678 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 2.100012e-01 | 0.678 | 1 | 1 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 2.100012e-01 | 0.678 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 2.100012e-01 | 0.678 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.100012e-01 | 0.678 | 0 | 0 |
| BDNF activates NTRK2 (TRKB) signaling | R-HSA-9024909 | 3.469232e-01 | 0.460 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.469232e-01 | 0.460 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 3.469232e-01 | 0.460 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 3.469232e-01 | 0.460 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.469232e-01 | 0.460 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 3.469232e-01 | 0.460 | 0 | 0 |
| Defective DHDDS causes RP59 | R-HSA-4755609 | 3.469232e-01 | 0.460 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 7.637889e-02 | 1.117 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 1.627152e-01 | 0.789 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 1.627152e-01 | 0.789 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 8.872546e-02 | 1.052 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.281200e-01 | 0.892 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 2.489806e-01 | 0.604 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 2.489806e-01 | 0.604 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.489806e-01 | 0.604 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 1.020402e-01 | 0.991 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 8.194444e-02 | 1.086 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.470431e-01 | 0.833 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.470431e-01 | 0.833 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.470431e-01 | 0.833 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 1.162858e-01 | 0.934 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 9.292417e-02 | 1.032 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.314174e-01 | 0.881 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 2.881513e-01 | 0.540 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 2.881513e-01 | 0.540 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 2.881513e-01 | 0.540 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 2.881513e-01 | 0.540 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 2.881513e-01 | 0.540 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.881513e-01 | 0.540 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 2.881513e-01 | 0.540 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 2.881513e-01 | 0.540 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 2.881513e-01 | 0.540 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 4.129188e-01 | 0.384 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 4.129188e-01 | 0.384 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 4.129188e-01 | 0.384 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.129188e-01 | 0.384 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 4.129188e-01 | 0.384 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 4.129188e-01 | 0.384 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 4.129188e-01 | 0.384 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 4.129188e-01 | 0.384 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 4.129188e-01 | 0.384 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 4.129188e-01 | 0.384 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 1.877804e-01 | 0.726 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.043346e-01 | 0.982 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 2.438022e-01 | 0.613 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 8.298868e-02 | 1.081 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 8.298868e-02 | 1.081 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 3.270772e-01 | 0.485 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 3.270772e-01 | 0.485 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 8.111783e-02 | 1.091 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.815821e-01 | 0.741 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 2.721740e-01 | 0.565 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 2.721740e-01 | 0.565 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 2.721740e-01 | 0.565 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 2.316113e-01 | 0.635 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 2.316113e-01 | 0.635 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 1.996878e-01 | 0.700 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 1.277990e-01 | 0.893 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 2.183741e-01 | 0.661 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 3.008677e-01 | 0.522 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 3.008677e-01 | 0.522 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 3.008677e-01 | 0.522 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.654080e-01 | 0.437 | 1 | 1 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 3.654080e-01 | 0.437 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 3.654080e-01 | 0.437 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.722489e-01 | 0.326 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 4.722489e-01 | 0.326 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 4.722489e-01 | 0.326 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 4.722489e-01 | 0.326 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 4.722489e-01 | 0.326 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 4.722489e-01 | 0.326 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 4.722489e-01 | 0.326 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.079786e-01 | 0.967 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.079786e-01 | 0.967 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.030399e-01 | 0.987 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 2.054638e-01 | 0.687 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 2.776111e-01 | 0.557 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.776111e-01 | 0.557 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 1.409033e-01 | 0.851 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 3.296975e-01 | 0.482 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 3.296975e-01 | 0.482 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 3.296975e-01 | 0.482 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 3.296975e-01 | 0.482 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 1.509406e-01 | 0.821 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 2.572076e-01 | 0.590 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 2.391429e-01 | 0.621 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 2.391429e-01 | 0.621 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 4.028668e-01 | 0.395 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 4.028668e-01 | 0.395 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 4.028668e-01 | 0.395 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 4.028668e-01 | 0.395 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 2.772131e-01 | 0.557 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 1.951918e-01 | 0.710 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 3.584948e-01 | 0.446 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.248874e-01 | 0.488 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 3.248874e-01 | 0.488 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.248874e-01 | 0.488 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 2.076859e-01 | 0.683 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 4.392384e-01 | 0.357 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 4.392384e-01 | 0.357 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 4.392384e-01 | 0.357 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 4.392384e-01 | 0.357 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 4.392384e-01 | 0.357 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.255862e-01 | 0.279 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 5.255862e-01 | 0.279 | 0 | 0 |
| IRS activation | R-HSA-74713 | 5.255862e-01 | 0.279 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.255862e-01 | 0.279 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 5.255862e-01 | 0.279 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 5.255862e-01 | 0.279 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 5.255862e-01 | 0.279 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.255862e-01 | 0.279 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 5.255862e-01 | 0.279 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 2.469701e-01 | 0.607 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 2.865665e-01 | 0.543 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 2.744523e-01 | 0.562 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.290687e-01 | 0.483 | 1 | 1 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 3.110809e-01 | 0.507 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 3.964201e-01 | 0.402 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 4.743603e-01 | 0.324 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.743603e-01 | 0.324 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 4.743603e-01 | 0.324 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 3.367243e-01 | 0.473 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 3.367243e-01 | 0.473 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 3.266074e-01 | 0.486 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 3.663131e-01 | 0.436 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 4.432635e-01 | 0.353 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 4.432635e-01 | 0.353 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 4.432635e-01 | 0.353 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 3.537216e-01 | 0.451 | 1 | 1 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 3.537216e-01 | 0.451 | 1 | 1 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 3.537216e-01 | 0.451 | 1 | 1 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 3.537216e-01 | 0.451 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 3.422640e-01 | 0.466 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 4.200703e-01 | 0.377 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 4.200703e-01 | 0.377 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 4.200703e-01 | 0.377 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 3.707989e-01 | 0.431 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 4.218975e-01 | 0.375 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 5.081136e-01 | 0.294 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 5.081136e-01 | 0.294 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 5.081136e-01 | 0.294 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 5.081136e-01 | 0.294 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 5.081136e-01 | 0.294 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 5.081136e-01 | 0.294 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 5.081136e-01 | 0.294 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 5.081136e-01 | 0.294 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 5.081136e-01 | 0.294 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 5.735358e-01 | 0.241 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 5.735358e-01 | 0.241 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.735358e-01 | 0.241 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 5.735358e-01 | 0.241 | 0 | 0 |
| Defective MTRR causes HMAE | R-HSA-3359467 | 5.735358e-01 | 0.241 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 5.735358e-01 | 0.241 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 5.735358e-01 | 0.241 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 3.149614e-01 | 0.502 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 4.223936e-01 | 0.374 | 1 | 1 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 4.223936e-01 | 0.374 | 1 | 1 |
| Dual Incision in GG-NER | R-HSA-5696400 | 4.424882e-01 | 0.354 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 4.666201e-01 | 0.331 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 4.409765e-01 | 0.356 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 4.206223e-01 | 0.376 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 5.404163e-01 | 0.267 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 5.404163e-01 | 0.267 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.404163e-01 | 0.267 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 5.404163e-01 | 0.267 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 5.404163e-01 | 0.267 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 4.027179e-01 | 0.395 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 5.232854e-01 | 0.281 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 5.232854e-01 | 0.281 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.730917e-01 | 0.325 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 5.117496e-01 | 0.291 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 4.524197e-01 | 0.344 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 5.485299e-01 | 0.261 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 5.485299e-01 | 0.261 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 5.485299e-01 | 0.261 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 5.485299e-01 | 0.261 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 5.712168e-01 | 0.243 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 5.712168e-01 | 0.243 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 5.712168e-01 | 0.243 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 5.712168e-01 | 0.243 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 4.714277e-01 | 0.327 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 5.418549e-01 | 0.266 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 5.550483e-01 | 0.256 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 5.729696e-01 | 0.242 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 5.729696e-01 | 0.242 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 5.729696e-01 | 0.242 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 5.607445e-01 | 0.251 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 6.004888e-01 | 0.221 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 6.004888e-01 | 0.221 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 6.004888e-01 | 0.221 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 6.004888e-01 | 0.221 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 6.004888e-01 | 0.221 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 6.004888e-01 | 0.221 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 5.792344e-01 | 0.237 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 5.962058e-01 | 0.225 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.818501e-01 | 0.550 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.099926e-01 | 0.959 | 0 | 0 |
| Protein folding | R-HSA-391251 | 2.055882e-01 | 0.687 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 5.117496e-01 | 0.291 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 3.387472e-01 | 0.470 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 3.149614e-01 | 0.502 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.517782e-01 | 0.819 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.572076e-01 | 0.590 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 4.050569e-01 | 0.392 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 5.225928e-01 | 0.282 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 2.541855e-01 | 0.595 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 3.031107e-01 | 0.518 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 5.336495e-01 | 0.273 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 2.655674e-01 | 0.576 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.165774e-01 | 0.664 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 7.799489e-02 | 1.108 | 1 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 4.503472e-01 | 0.346 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.949470e-01 | 0.710 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 5.168706e-01 | 0.287 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 5.154166e-01 | 0.288 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 5.869455e-01 | 0.231 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 4.743603e-01 | 0.324 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 4.409765e-01 | 0.356 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 5.000555e-01 | 0.301 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.610022e-01 | 0.793 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 7.574970e-02 | 1.121 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.384575e-01 | 0.623 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.336508e-01 | 0.874 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 4.958692e-01 | 0.305 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 7.838330e-02 | 1.106 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.314174e-01 | 0.881 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 2.772131e-01 | 0.557 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 3.356556e-01 | 0.474 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 4.705859e-01 | 0.327 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.004888e-01 | 0.221 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 2.484460e-01 | 0.605 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.824241e-01 | 0.739 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.103049e-01 | 0.957 | 1 | 1 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.831099e-01 | 0.737 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 3.129313e-01 | 0.505 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 2.702460e-01 | 0.568 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 3.964201e-01 | 0.402 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 3.127713e-01 | 0.505 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.531973e-01 | 0.344 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 5.232854e-01 | 0.281 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.680206e-01 | 0.434 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 2.267553e-01 | 0.644 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 2.267553e-01 | 0.644 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 4.666201e-01 | 0.331 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 5.905423e-01 | 0.229 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 2.100012e-01 | 0.678 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 8.872546e-02 | 1.052 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 1.669672e-01 | 0.777 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.171137e-01 | 0.931 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.171137e-01 | 0.931 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.654080e-01 | 0.437 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 3.654080e-01 | 0.437 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 4.028668e-01 | 0.395 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 4.392384e-01 | 0.357 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 5.729696e-01 | 0.242 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 5.729696e-01 | 0.242 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 5.468833e-01 | 0.262 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 5.759105e-01 | 0.240 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.706415e-01 | 0.244 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 4.958692e-01 | 0.305 | 1 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 5.755902e-01 | 0.240 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.304947e-01 | 0.637 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 3.076300e-01 | 0.512 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 3.537216e-01 | 0.451 | 1 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 4.830776e-01 | 0.316 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 9.208460e-02 | 1.036 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 2.428180e-01 | 0.615 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 7.838330e-02 | 1.106 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 9.369656e-02 | 1.028 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 2.100012e-01 | 0.678 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 7.637889e-02 | 1.117 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 3.270772e-01 | 0.485 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 3.270772e-01 | 0.485 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 1.996878e-01 | 0.700 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 3.654080e-01 | 0.437 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 3.106240e-01 | 0.508 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 5.081136e-01 | 0.294 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 5.404163e-01 | 0.267 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 5.232854e-01 | 0.281 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 5.389781e-01 | 0.268 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 5.990943e-01 | 0.223 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 2.923605e-01 | 0.534 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 1.270307e-01 | 0.896 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 2.503801e-01 | 0.601 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 4.576781e-01 | 0.339 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 2.818501e-01 | 0.550 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 8.411808e-02 | 1.075 | 1 | 0 |
| Vasopressin-like receptors | R-HSA-388479 | 1.348842e-01 | 0.870 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 4.028668e-01 | 0.395 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 5.081136e-01 | 0.294 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 4.830776e-01 | 0.316 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 5.029890e-01 | 0.298 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 5.336495e-01 | 0.273 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 2.183741e-01 | 0.661 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.320455e-01 | 0.879 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 2.229890e-01 | 0.652 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 4.434929e-01 | 0.353 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.263133e-01 | 0.899 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.208712e-01 | 0.656 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 5.485299e-01 | 0.261 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 5.759105e-01 | 0.240 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.908398e-01 | 0.719 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 1.717506e-01 | 0.765 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.377954e-01 | 0.861 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 7.637889e-02 | 1.117 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.020402e-01 | 0.991 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.020402e-01 | 0.991 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 2.881513e-01 | 0.540 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 9.387963e-02 | 1.027 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.093672e-01 | 0.679 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 3.270772e-01 | 0.485 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 3.270772e-01 | 0.485 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.270307e-01 | 0.896 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 4.028668e-01 | 0.395 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 3.584948e-01 | 0.446 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 3.584948e-01 | 0.446 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 2.975173e-01 | 0.526 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 2.743265e-01 | 0.562 | 1 | 1 |
| Synthesis of DNA | R-HSA-69239 | 1.411321e-01 | 0.850 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 2.508462e-01 | 0.601 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 4.392384e-01 | 0.357 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 5.255862e-01 | 0.279 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 5.255862e-01 | 0.279 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 5.255862e-01 | 0.279 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 2.865665e-01 | 0.543 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 4.743603e-01 | 0.324 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 4.011736e-01 | 0.397 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 4.434929e-01 | 0.353 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 5.328152e-01 | 0.273 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 6.004888e-01 | 0.221 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 5.418549e-01 | 0.266 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 2.384575e-01 | 0.623 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 4.280184e-01 | 0.369 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 4.880370e-01 | 0.312 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 2.384212e-01 | 0.623 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 3.773907e-01 | 0.423 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 3.707989e-01 | 0.431 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 5.404163e-01 | 0.267 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 2.543971e-01 | 0.594 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.367243e-01 | 0.473 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 4.944565e-01 | 0.306 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 5.714845e-01 | 0.243 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.669672e-01 | 0.777 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.815821e-01 | 0.741 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.609534e-01 | 0.583 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 4.562183e-01 | 0.341 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.950454e-01 | 0.305 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.921644e-01 | 0.308 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 6.004888e-01 | 0.221 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.296517e-01 | 0.639 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 1.487164e-01 | 0.828 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 9.106803e-02 | 1.041 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 3.270772e-01 | 0.485 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 2.375709e-01 | 0.624 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 2.661630e-01 | 0.575 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 2.881513e-01 | 0.540 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.438022e-01 | 0.613 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.438022e-01 | 0.613 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.438022e-01 | 0.613 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 4.722489e-01 | 0.326 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 4.722489e-01 | 0.326 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 4.028668e-01 | 0.395 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 4.392384e-01 | 0.357 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 5.255862e-01 | 0.279 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 5.255862e-01 | 0.279 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 4.154037e-01 | 0.382 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 3.803693e-01 | 0.420 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 3.663131e-01 | 0.436 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 4.705859e-01 | 0.327 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 5.735358e-01 | 0.241 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 4.050569e-01 | 0.392 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 4.666201e-01 | 0.331 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 4.524428e-01 | 0.344 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 4.798421e-01 | 0.319 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 4.432635e-01 | 0.353 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.996878e-01 | 0.700 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 2.776111e-01 | 0.557 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 3.487438e-01 | 0.457 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 5.089585e-01 | 0.293 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.188668e-01 | 0.925 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 5.227951e-01 | 0.282 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.652626e-01 | 0.782 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 4.434929e-01 | 0.353 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 3.198420e-01 | 0.495 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 1.281200e-01 | 0.892 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.975173e-01 | 0.526 | 1 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.964201e-01 | 0.402 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 3.317179e-01 | 0.479 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 4.037287e-01 | 0.394 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 5.759105e-01 | 0.240 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 3.356556e-01 | 0.474 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.851980e-02 | 1.105 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 9.031404e-02 | 1.044 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 3.121600e-01 | 0.506 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.264436e-01 | 0.898 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 5.233318e-01 | 0.281 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.074837e-01 | 0.683 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 1.145047e-01 | 0.941 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.263551e-01 | 0.645 | 1 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 2.180989e-01 | 0.661 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 4.154037e-01 | 0.382 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.705859e-01 | 0.327 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 5.336495e-01 | 0.273 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 8.658820e-02 | 1.063 | 1 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.083204e-01 | 0.965 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 2.808456e-01 | 0.552 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 7.223463e-02 | 1.141 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 1.426340e-01 | 0.846 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 2.093672e-01 | 0.679 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 1.270307e-01 | 0.896 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.050569e-01 | 0.392 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.050569e-01 | 0.392 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.808182e-01 | 0.743 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 1.438177e-01 | 0.842 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 3.110824e-01 | 0.507 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 8.244281e-02 | 1.084 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.824241e-01 | 0.739 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 4.320943e-01 | 0.364 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.736692e-01 | 0.760 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 2.625084e-01 | 0.581 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.450309e-01 | 0.839 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.649301e-01 | 0.783 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.944782e-01 | 0.711 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.141393e-01 | 0.943 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.355304e-01 | 0.868 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 5.438380e-01 | 0.265 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 2.384575e-01 | 0.623 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 3.106240e-01 | 0.508 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 2.303202e-01 | 0.638 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 1.001954e-01 | 0.999 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 2.735136e-01 | 0.563 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 2.735136e-01 | 0.563 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.377954e-01 | 0.861 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 2.100012e-01 | 0.678 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.469232e-01 | 0.460 | 0 | 0 |
| Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization | R-HSA-180897 | 3.469232e-01 | 0.460 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.020402e-01 | 0.991 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 1.020402e-01 | 0.991 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 4.129188e-01 | 0.384 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 4.129188e-01 | 0.384 | 0 | 0 |
| The IPAF inflammasome | R-HSA-844623 | 4.129188e-01 | 0.384 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 2.438022e-01 | 0.613 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 2.721740e-01 | 0.565 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.519900e-01 | 0.818 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.543971e-01 | 0.594 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 2.543971e-01 | 0.594 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 3.008677e-01 | 0.522 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 4.722489e-01 | 0.326 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 4.722489e-01 | 0.326 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 1.380530e-01 | 0.860 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.932595e-01 | 0.714 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 2.084210e-01 | 0.681 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 2.975173e-01 | 0.526 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 2.702460e-01 | 0.568 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 3.180510e-01 | 0.498 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 4.392384e-01 | 0.357 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.743603e-01 | 0.324 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 4.743603e-01 | 0.324 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 4.432635e-01 | 0.353 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.200703e-01 | 0.377 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 3.317179e-01 | 0.479 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 5.081136e-01 | 0.294 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 5.735358e-01 | 0.241 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 5.735358e-01 | 0.241 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 5.735358e-01 | 0.241 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 5.735358e-01 | 0.241 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 5.735358e-01 | 0.241 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 2.986508e-01 | 0.525 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 5.404163e-01 | 0.267 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 5.404163e-01 | 0.267 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 4.898290e-01 | 0.310 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 5.154166e-01 | 0.288 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 5.550483e-01 | 0.256 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 5.495888e-01 | 0.260 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 6.004888e-01 | 0.221 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 5.869455e-01 | 0.231 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.702460e-01 | 0.568 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 3.254518e-01 | 0.488 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 4.192706e-01 | 0.378 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 5.712168e-01 | 0.243 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 3.411505e-01 | 0.467 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 4.043538e-01 | 0.393 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 3.537216e-01 | 0.451 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 1.076399e-01 | 0.968 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 1.473830e-01 | 0.832 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 1.450309e-01 | 0.839 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 5.275831e-01 | 0.278 | 1 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.975173e-01 | 0.526 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 5.962058e-01 | 0.225 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 3.367243e-01 | 0.473 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 3.367243e-01 | 0.473 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 6.004888e-01 | 0.221 | 1 | 1 |
| Regulation of TP53 Activity | R-HSA-5633007 | 2.702812e-01 | 0.568 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 8.556941e-02 | 1.068 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 2.469701e-01 | 0.607 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 2.774353e-01 | 0.557 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 2.438022e-01 | 0.613 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 3.654080e-01 | 0.437 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 2.391429e-01 | 0.621 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 1.013218e-01 | 0.994 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 4.043671e-01 | 0.393 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.689251e-01 | 0.329 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 5.698206e-01 | 0.244 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 5.698206e-01 | 0.244 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 3.463798e-01 | 0.460 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 3.463798e-01 | 0.460 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 5.769534e-01 | 0.239 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 1.996878e-01 | 0.700 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.334710e-01 | 0.875 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.255862e-01 | 0.279 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.031107e-01 | 0.518 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 3.580226e-01 | 0.446 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 5.029890e-01 | 0.298 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 5.336495e-01 | 0.273 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 7.799489e-02 | 1.108 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 9.357741e-02 | 1.029 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.852220e-01 | 0.545 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 4.531973e-01 | 0.344 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 1.162858e-01 | 0.934 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 5.973008e-01 | 0.224 | 1 | 1 |
| Nervous system development | R-HSA-9675108 | 1.764289e-01 | 0.753 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 2.220911e-01 | 0.653 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.246370e-01 | 0.904 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 1.143361e-01 | 0.942 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 2.100012e-01 | 0.678 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 6.790366e-02 | 1.168 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 2.881513e-01 | 0.540 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 1.815821e-01 | 0.741 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 3.008677e-01 | 0.522 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 4.722489e-01 | 0.326 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 4.028668e-01 | 0.395 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 4.432635e-01 | 0.353 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 5.081136e-01 | 0.294 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 5.404163e-01 | 0.267 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 5.990943e-01 | 0.223 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 4.893905e-01 | 0.310 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 5.927488e-01 | 0.227 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.435889e-01 | 0.843 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 5.081136e-01 | 0.294 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 8.203002e-02 | 1.086 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.761024e-01 | 0.754 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 5.860858e-01 | 0.232 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 9.258442e-02 | 1.033 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 3.106240e-01 | 0.508 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 4.200703e-01 | 0.377 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 5.081136e-01 | 0.294 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 5.081136e-01 | 0.294 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 5.117496e-01 | 0.291 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.237361e-01 | 0.373 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 7.581296e-02 | 1.120 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.028668e-01 | 0.395 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.304947e-01 | 0.637 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 1.046541e-01 | 0.980 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.036434e-01 | 0.984 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 1.162858e-01 | 0.934 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.270307e-01 | 0.896 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.503472e-01 | 0.346 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 5.962058e-01 | 0.225 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 5.081136e-01 | 0.294 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 3.149614e-01 | 0.502 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.831850e-01 | 0.234 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 5.965676e-01 | 0.224 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 5.860858e-01 | 0.232 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 2.066698e-01 | 0.685 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 3.469232e-01 | 0.460 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.489806e-01 | 0.604 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 4.129188e-01 | 0.384 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 2.721740e-01 | 0.565 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 2.721740e-01 | 0.565 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 1.392379e-01 | 0.856 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 4.722489e-01 | 0.326 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 9.501742e-02 | 1.022 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 3.110809e-01 | 0.507 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 4.743603e-01 | 0.324 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 2.578313e-01 | 0.589 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 5.735358e-01 | 0.241 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 4.531973e-01 | 0.344 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 5.232854e-01 | 0.281 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 5.759105e-01 | 0.240 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 6.004888e-01 | 0.221 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 4.755718e-01 | 0.323 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 3.897349e-01 | 0.409 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 4.972842e-01 | 0.303 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 4.317230e-01 | 0.365 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 2.702460e-01 | 0.568 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 3.537216e-01 | 0.451 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.450309e-01 | 0.839 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.143361e-01 | 0.942 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.377954e-01 | 0.861 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.470431e-01 | 0.833 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 3.387472e-01 | 0.470 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 4.503472e-01 | 0.346 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 5.226998e-01 | 0.282 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 4.028668e-01 | 0.395 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 4.011736e-01 | 0.397 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 3.558607e-01 | 0.449 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 4.972842e-01 | 0.303 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 5.417266e-01 | 0.266 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.726174e-01 | 0.429 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 3.738554e-01 | 0.427 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 1.717506e-01 | 0.765 | 0 | 0 |
| The AIM2 inflammasome | R-HSA-844615 | 3.469232e-01 | 0.460 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.881513e-01 | 0.540 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.093672e-01 | 0.679 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.450309e-01 | 0.839 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.654080e-01 | 0.437 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 4.722489e-01 | 0.326 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.722489e-01 | 0.326 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 4.028668e-01 | 0.395 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 3.584948e-01 | 0.446 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 2.975173e-01 | 0.526 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 5.255862e-01 | 0.279 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.255862e-01 | 0.279 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 4.743603e-01 | 0.324 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 4.432635e-01 | 0.353 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 5.404163e-01 | 0.267 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 5.485299e-01 | 0.261 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.924805e-01 | 0.716 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 2.229890e-01 | 0.652 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 4.830776e-01 | 0.316 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.867629e-01 | 0.729 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.302772e-01 | 0.885 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 3.485089e-01 | 0.458 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 6.004888e-01 | 0.221 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 3.110809e-01 | 0.507 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 4.035822e-01 | 0.394 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.654080e-01 | 0.437 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 5.729696e-01 | 0.242 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.790288e-01 | 0.747 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 5.604583e-01 | 0.251 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.470431e-01 | 0.833 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 2.881513e-01 | 0.540 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.270772e-01 | 0.485 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 2.222461e-01 | 0.653 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 5.255862e-01 | 0.279 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 5.255862e-01 | 0.279 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 5.735358e-01 | 0.241 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 5.712168e-01 | 0.243 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 5.755902e-01 | 0.240 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.316113e-01 | 0.635 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 6.004888e-01 | 0.221 | 0 | 0 |
| Regulation of gene expression in early pancreatic precursor cells | R-HSA-210747 | 4.392384e-01 | 0.357 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 4.424882e-01 | 0.354 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 5.404163e-01 | 0.267 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 5.712168e-01 | 0.243 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 4.616371e-01 | 0.336 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 4.743603e-01 | 0.324 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 7.852122e-02 | 1.105 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 6.004888e-01 | 0.221 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 3.008677e-01 | 0.522 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 6.036001e-01 | 0.219 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 6.110671e-01 | 0.214 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 6.149234e-01 | 0.211 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 6.151716e-01 | 0.211 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 6.159097e-01 | 0.210 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 6.159097e-01 | 0.210 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 6.166416e-01 | 0.210 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 6.166416e-01 | 0.210 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.166416e-01 | 0.210 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.166416e-01 | 0.210 | 0 | 0 |
| Defective MTR causes HMAG | R-HSA-3359469 | 6.166416e-01 | 0.210 | 0 | 0 |
| Defective CYP11A1 causes AICSR | R-HSA-5579026 | 6.166416e-01 | 0.210 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 6.166416e-01 | 0.210 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 6.166416e-01 | 0.210 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 6.166416e-01 | 0.210 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 6.166416e-01 | 0.210 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 6.166416e-01 | 0.210 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 6.166416e-01 | 0.210 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 6.166416e-01 | 0.210 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.166416e-01 | 0.210 | 0 | 0 |
| Metabolism of vitamin K | R-HSA-6806664 | 6.166416e-01 | 0.210 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 6.166416e-01 | 0.210 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 6.166416e-01 | 0.210 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.166416e-01 | 0.210 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 6.174946e-01 | 0.209 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 6.192966e-01 | 0.208 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 6.192966e-01 | 0.208 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 6.192966e-01 | 0.208 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 6.209460e-01 | 0.207 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 6.238600e-01 | 0.205 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 6.248609e-01 | 0.204 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 6.282266e-01 | 0.202 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 6.282266e-01 | 0.202 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 6.282266e-01 | 0.202 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 6.282266e-01 | 0.202 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 6.282266e-01 | 0.202 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 6.282266e-01 | 0.202 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.282266e-01 | 0.202 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 6.282266e-01 | 0.202 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 6.282266e-01 | 0.202 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 6.306856e-01 | 0.200 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 6.308804e-01 | 0.200 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 6.320850e-01 | 0.199 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 6.331097e-01 | 0.199 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 6.350025e-01 | 0.197 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 6.350025e-01 | 0.197 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 6.350025e-01 | 0.197 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 6.350025e-01 | 0.197 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 6.350025e-01 | 0.197 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 6.371493e-01 | 0.196 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 6.375669e-01 | 0.195 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 6.411382e-01 | 0.193 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 6.411382e-01 | 0.193 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 6.411382e-01 | 0.193 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 6.415882e-01 | 0.193 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 6.444883e-01 | 0.191 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 6.446061e-01 | 0.191 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 6.449328e-01 | 0.190 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 6.451182e-01 | 0.190 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 6.487711e-01 | 0.188 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 6.487711e-01 | 0.188 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 6.534513e-01 | 0.185 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 6.534692e-01 | 0.185 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 6.544413e-01 | 0.184 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 6.544413e-01 | 0.184 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 6.544413e-01 | 0.184 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 6.553927e-01 | 0.183 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 6.553927e-01 | 0.183 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 6.553927e-01 | 0.183 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 6.553927e-01 | 0.183 | 0 | 0 |
| Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2 | R-HSA-964827 | 6.553927e-01 | 0.183 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 6.553927e-01 | 0.183 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 6.553927e-01 | 0.183 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 6.553927e-01 | 0.183 | 0 | 0 |
| Reuptake of GABA | R-HSA-888593 | 6.553927e-01 | 0.183 | 0 | 0 |
| Electron transport from NADPH to Ferredoxin | R-HSA-2395516 | 6.553927e-01 | 0.183 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 6.553927e-01 | 0.183 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 6.553927e-01 | 0.183 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 6.553927e-01 | 0.183 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 6.553927e-01 | 0.183 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 6.553927e-01 | 0.183 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 6.569784e-01 | 0.182 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 6.575694e-01 | 0.182 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 6.611441e-01 | 0.180 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 6.611441e-01 | 0.180 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 6.620816e-01 | 0.179 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 6.620816e-01 | 0.179 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 6.649706e-01 | 0.177 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 6.649706e-01 | 0.177 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 6.649706e-01 | 0.177 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 6.682642e-01 | 0.175 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 6.703631e-01 | 0.174 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 6.712991e-01 | 0.173 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 6.712991e-01 | 0.173 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 6.712991e-01 | 0.173 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 6.712991e-01 | 0.173 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 6.756797e-01 | 0.170 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.791573e-01 | 0.168 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 6.791573e-01 | 0.168 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 6.791573e-01 | 0.168 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 6.791573e-01 | 0.168 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 6.791573e-01 | 0.168 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 6.791573e-01 | 0.168 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 6.806746e-01 | 0.167 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 6.809628e-01 | 0.167 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 6.821234e-01 | 0.166 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 6.828632e-01 | 0.166 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 6.838907e-01 | 0.165 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 6.856825e-01 | 0.164 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 6.884855e-01 | 0.162 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 6.898080e-01 | 0.161 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 6.902287e-01 | 0.161 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 6.902287e-01 | 0.161 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 6.902287e-01 | 0.161 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 6.902287e-01 | 0.161 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 6.902287e-01 | 0.161 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 6.902287e-01 | 0.161 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 6.902287e-01 | 0.161 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 6.902287e-01 | 0.161 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 6.902287e-01 | 0.161 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 6.902287e-01 | 0.161 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 6.902287e-01 | 0.161 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 6.902287e-01 | 0.161 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 6.902287e-01 | 0.161 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 6.902287e-01 | 0.161 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 6.902287e-01 | 0.161 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 6.905509e-01 | 0.161 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 6.908096e-01 | 0.161 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 6.976337e-01 | 0.156 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 6.985793e-01 | 0.156 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 6.985793e-01 | 0.156 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 7.012658e-01 | 0.154 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 7.012658e-01 | 0.154 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 7.024097e-01 | 0.153 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 7.024097e-01 | 0.153 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 7.024097e-01 | 0.153 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 7.024097e-01 | 0.153 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 7.035238e-01 | 0.153 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 7.050253e-01 | 0.152 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.102025e-01 | 0.149 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 7.111247e-01 | 0.148 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 7.116817e-01 | 0.148 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 7.168235e-01 | 0.145 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 7.168235e-01 | 0.145 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 7.185529e-01 | 0.144 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 7.195165e-01 | 0.143 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 7.195165e-01 | 0.143 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.195165e-01 | 0.143 | 1 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 7.195165e-01 | 0.143 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 7.201659e-01 | 0.143 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 7.215451e-01 | 0.142 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 7.215451e-01 | 0.142 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.215451e-01 | 0.142 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 7.215451e-01 | 0.142 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 7.215451e-01 | 0.142 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 7.215451e-01 | 0.142 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 7.215451e-01 | 0.142 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 7.215451e-01 | 0.142 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 7.215451e-01 | 0.142 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 7.215451e-01 | 0.142 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 7.215451e-01 | 0.142 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 7.215451e-01 | 0.142 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 7.215451e-01 | 0.142 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 7.215451e-01 | 0.142 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 7.215451e-01 | 0.142 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 7.215451e-01 | 0.142 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 7.233158e-01 | 0.141 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 7.233158e-01 | 0.141 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 7.233158e-01 | 0.141 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 7.233158e-01 | 0.141 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 7.242418e-01 | 0.140 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 7.242418e-01 | 0.140 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 7.242418e-01 | 0.140 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 7.242418e-01 | 0.140 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 7.242418e-01 | 0.140 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 7.242418e-01 | 0.140 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 7.247632e-01 | 0.140 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 7.297052e-01 | 0.137 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 7.297052e-01 | 0.137 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 7.297052e-01 | 0.137 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 7.297052e-01 | 0.137 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 7.297052e-01 | 0.137 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 7.297052e-01 | 0.137 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 7.298347e-01 | 0.137 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 7.351506e-01 | 0.134 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 7.361683e-01 | 0.133 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 7.361683e-01 | 0.133 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 7.361683e-01 | 0.133 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 7.361683e-01 | 0.133 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 7.361683e-01 | 0.133 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 7.368877e-01 | 0.133 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 7.368877e-01 | 0.133 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 7.384457e-01 | 0.132 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 7.384457e-01 | 0.132 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 7.421681e-01 | 0.129 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 7.421681e-01 | 0.129 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 7.447030e-01 | 0.128 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 7.447030e-01 | 0.128 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 7.447030e-01 | 0.128 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 7.447030e-01 | 0.128 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 7.447030e-01 | 0.128 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 7.447030e-01 | 0.128 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 7.447030e-01 | 0.128 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 7.447030e-01 | 0.128 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 7.496972e-01 | 0.125 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 7.496972e-01 | 0.125 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 7.496972e-01 | 0.125 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 7.496972e-01 | 0.125 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 7.496972e-01 | 0.125 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 7.496972e-01 | 0.125 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 7.496972e-01 | 0.125 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 7.496972e-01 | 0.125 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 7.496972e-01 | 0.125 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 7.496972e-01 | 0.125 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 7.496972e-01 | 0.125 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 7.496972e-01 | 0.125 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 7.507802e-01 | 0.124 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 7.507802e-01 | 0.124 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 7.507802e-01 | 0.124 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 7.514649e-01 | 0.124 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 7.516232e-01 | 0.124 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 7.533955e-01 | 0.123 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 7.533955e-01 | 0.123 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 7.533955e-01 | 0.123 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 7.612735e-01 | 0.118 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 7.615528e-01 | 0.118 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 7.638474e-01 | 0.117 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 7.638474e-01 | 0.117 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 7.638474e-01 | 0.117 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 7.638474e-01 | 0.117 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 7.638474e-01 | 0.117 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 7.638474e-01 | 0.117 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 7.638474e-01 | 0.117 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 7.642995e-01 | 0.117 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 7.642995e-01 | 0.117 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 7.647622e-01 | 0.116 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 7.647622e-01 | 0.116 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 7.647622e-01 | 0.116 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 7.647622e-01 | 0.116 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 7.690590e-01 | 0.114 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 7.718490e-01 | 0.112 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 7.750045e-01 | 0.111 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 7.750045e-01 | 0.111 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 7.750045e-01 | 0.111 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 7.750045e-01 | 0.111 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 7.750045e-01 | 0.111 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 7.750045e-01 | 0.111 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 7.750045e-01 | 0.111 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 7.750045e-01 | 0.111 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 7.750045e-01 | 0.111 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 7.750045e-01 | 0.111 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 7.750045e-01 | 0.111 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 7.750045e-01 | 0.111 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 7.754651e-01 | 0.110 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 7.764798e-01 | 0.110 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.764798e-01 | 0.110 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 7.770576e-01 | 0.110 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 7.781245e-01 | 0.109 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 7.789252e-01 | 0.109 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 7.795337e-01 | 0.108 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 7.817319e-01 | 0.107 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 7.817319e-01 | 0.107 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 7.817319e-01 | 0.107 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 7.839003e-01 | 0.106 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 7.839003e-01 | 0.106 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 7.839003e-01 | 0.106 | 1 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 7.839003e-01 | 0.106 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 7.839003e-01 | 0.106 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 7.881517e-01 | 0.103 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 7.881517e-01 | 0.103 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 7.889849e-01 | 0.103 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 7.889849e-01 | 0.103 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 7.890455e-01 | 0.103 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 7.890455e-01 | 0.103 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 7.908786e-01 | 0.102 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 7.908786e-01 | 0.102 | 1 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 7.908786e-01 | 0.102 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 7.917753e-01 | 0.101 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 7.977545e-01 | 0.098 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 7.977545e-01 | 0.098 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 7.977545e-01 | 0.098 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 7.977545e-01 | 0.098 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 7.977545e-01 | 0.098 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 7.977545e-01 | 0.098 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 7.977545e-01 | 0.098 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 7.977545e-01 | 0.098 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 7.977545e-01 | 0.098 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 7.979435e-01 | 0.098 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 7.979435e-01 | 0.098 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 7.979435e-01 | 0.098 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 7.983088e-01 | 0.098 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 7.984157e-01 | 0.098 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.984157e-01 | 0.098 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 7.984157e-01 | 0.098 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.984157e-01 | 0.098 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 7.984157e-01 | 0.098 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 7.986967e-01 | 0.098 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 8.030379e-01 | 0.095 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 8.030379e-01 | 0.095 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 8.046486e-01 | 0.094 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 8.080648e-01 | 0.093 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 8.081446e-01 | 0.093 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 8.082962e-01 | 0.092 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 8.089198e-01 | 0.092 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 8.101159e-01 | 0.091 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 8.103868e-01 | 0.091 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 8.103868e-01 | 0.091 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 8.103868e-01 | 0.091 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 8.112142e-01 | 0.091 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 8.112142e-01 | 0.091 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 8.112142e-01 | 0.091 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 8.112142e-01 | 0.091 | 1 | 0 |
| Mitophagy | R-HSA-5205647 | 8.112142e-01 | 0.091 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 8.112142e-01 | 0.091 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 8.112142e-01 | 0.091 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 8.139586e-01 | 0.089 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 8.139586e-01 | 0.089 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 8.139586e-01 | 0.089 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 8.139586e-01 | 0.089 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 8.146023e-01 | 0.089 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 8.146170e-01 | 0.089 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 8.146170e-01 | 0.089 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 8.146170e-01 | 0.089 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 8.170938e-01 | 0.088 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 8.182053e-01 | 0.087 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.182053e-01 | 0.087 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.182053e-01 | 0.087 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.182053e-01 | 0.087 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 8.182053e-01 | 0.087 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 8.182053e-01 | 0.087 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 8.182053e-01 | 0.087 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 8.182053e-01 | 0.087 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 8.182053e-01 | 0.087 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 8.182053e-01 | 0.087 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 8.198516e-01 | 0.086 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 8.216120e-01 | 0.085 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 8.221823e-01 | 0.085 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 8.237398e-01 | 0.084 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 8.237398e-01 | 0.084 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 8.237398e-01 | 0.084 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 8.237398e-01 | 0.084 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.256314e-01 | 0.083 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.256314e-01 | 0.083 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 8.256314e-01 | 0.083 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 8.256509e-01 | 0.083 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 8.256509e-01 | 0.083 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 8.263272e-01 | 0.083 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 8.284206e-01 | 0.082 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 8.284206e-01 | 0.082 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 8.355481e-01 | 0.078 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 8.355481e-01 | 0.078 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 8.360977e-01 | 0.078 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 8.360977e-01 | 0.078 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 8.365893e-01 | 0.077 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 8.365893e-01 | 0.077 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 8.365893e-01 | 0.077 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 8.365893e-01 | 0.077 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 8.365893e-01 | 0.077 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 8.365893e-01 | 0.077 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.365893e-01 | 0.077 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 8.395873e-01 | 0.076 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 8.402562e-01 | 0.076 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 8.412216e-01 | 0.075 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 8.418615e-01 | 0.075 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.418615e-01 | 0.075 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 8.418615e-01 | 0.075 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.418615e-01 | 0.075 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 8.431594e-01 | 0.074 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 8.433743e-01 | 0.074 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.438689e-01 | 0.074 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 8.440666e-01 | 0.074 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 8.444437e-01 | 0.073 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 8.460330e-01 | 0.073 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 8.466679e-01 | 0.072 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 8.466679e-01 | 0.072 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 8.483883e-01 | 0.071 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 8.483883e-01 | 0.071 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 8.485358e-01 | 0.071 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 8.485839e-01 | 0.071 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.515470e-01 | 0.070 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 8.525659e-01 | 0.069 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 8.531151e-01 | 0.069 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 8.531151e-01 | 0.069 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 8.531151e-01 | 0.069 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 8.531151e-01 | 0.069 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.531151e-01 | 0.069 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 8.531151e-01 | 0.069 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 8.531151e-01 | 0.069 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.531151e-01 | 0.069 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 8.531151e-01 | 0.069 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.531151e-01 | 0.069 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 8.531151e-01 | 0.069 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 8.537502e-01 | 0.069 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 8.543397e-01 | 0.068 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 8.543397e-01 | 0.068 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 8.543397e-01 | 0.068 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 8.543397e-01 | 0.068 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 8.543397e-01 | 0.068 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 8.543397e-01 | 0.068 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 8.548483e-01 | 0.068 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 8.548707e-01 | 0.068 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 8.554550e-01 | 0.068 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 8.567973e-01 | 0.067 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 8.571281e-01 | 0.067 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 8.571281e-01 | 0.067 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 8.613361e-01 | 0.065 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 8.651920e-01 | 0.063 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 8.651920e-01 | 0.063 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 8.651920e-01 | 0.063 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.659125e-01 | 0.063 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 8.659125e-01 | 0.063 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 8.659125e-01 | 0.063 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 8.659125e-01 | 0.063 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 8.659125e-01 | 0.063 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 8.659125e-01 | 0.063 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 8.659125e-01 | 0.063 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 8.669579e-01 | 0.062 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 8.669579e-01 | 0.062 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 8.669579e-01 | 0.062 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.669579e-01 | 0.062 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 8.679706e-01 | 0.061 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 8.679706e-01 | 0.061 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 8.679706e-01 | 0.061 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.679706e-01 | 0.061 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 8.679706e-01 | 0.061 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 8.679706e-01 | 0.061 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 8.679706e-01 | 0.061 | 0 | 0 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | R-HSA-9837092 | 8.679706e-01 | 0.061 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.679706e-01 | 0.061 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 8.679706e-01 | 0.061 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 8.679706e-01 | 0.061 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.679706e-01 | 0.061 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 8.679706e-01 | 0.061 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 8.712980e-01 | 0.060 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 8.728316e-01 | 0.059 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 8.753423e-01 | 0.058 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 8.761864e-01 | 0.057 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 8.761864e-01 | 0.057 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 8.761864e-01 | 0.057 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 8.761864e-01 | 0.057 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 8.761864e-01 | 0.057 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 8.766354e-01 | 0.057 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 8.766354e-01 | 0.057 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.766354e-01 | 0.057 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 8.766354e-01 | 0.057 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 8.796656e-01 | 0.056 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 8.808230e-01 | 0.055 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.808230e-01 | 0.055 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 8.813244e-01 | 0.055 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.813244e-01 | 0.055 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 8.813244e-01 | 0.055 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 8.813244e-01 | 0.055 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 8.813244e-01 | 0.055 | 0 | 0 |
| Mitochondrial Uncoupling | R-HSA-166187 | 8.813244e-01 | 0.055 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 8.813244e-01 | 0.055 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 8.813244e-01 | 0.055 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 8.813890e-01 | 0.055 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.865617e-01 | 0.052 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 8.865617e-01 | 0.052 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 8.865617e-01 | 0.052 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 8.865617e-01 | 0.052 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 8.865617e-01 | 0.052 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.865617e-01 | 0.052 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.883742e-01 | 0.051 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 8.883742e-01 | 0.051 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 8.883742e-01 | 0.051 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 8.883956e-01 | 0.051 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.906461e-01 | 0.050 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.921279e-01 | 0.050 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 8.927552e-01 | 0.049 | 1 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 8.927552e-01 | 0.049 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 8.927552e-01 | 0.049 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 8.927552e-01 | 0.049 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 8.928201e-01 | 0.049 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 8.929534e-01 | 0.049 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 8.929534e-01 | 0.049 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 8.933283e-01 | 0.049 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 8.933283e-01 | 0.049 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 8.933283e-01 | 0.049 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 8.933283e-01 | 0.049 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 8.933283e-01 | 0.049 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 8.933283e-01 | 0.049 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.933283e-01 | 0.049 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 8.933283e-01 | 0.049 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 8.933283e-01 | 0.049 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 8.933283e-01 | 0.049 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.933283e-01 | 0.049 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 8.933283e-01 | 0.049 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 8.938995e-01 | 0.049 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 8.957430e-01 | 0.048 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 8.957430e-01 | 0.048 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 8.957430e-01 | 0.048 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 8.968922e-01 | 0.047 | 1 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 8.973733e-01 | 0.047 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.005481e-01 | 0.045 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.041186e-01 | 0.044 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 9.041186e-01 | 0.044 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 9.041186e-01 | 0.044 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 9.041186e-01 | 0.044 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.042283e-01 | 0.044 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 9.057249e-01 | 0.043 | 1 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 9.080847e-01 | 0.042 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 9.085700e-01 | 0.042 | 1 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 9.085700e-01 | 0.042 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 9.127624e-01 | 0.040 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 9.132838e-01 | 0.039 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 9.138181e-01 | 0.039 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 9.138181e-01 | 0.039 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 9.138181e-01 | 0.039 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 9.138181e-01 | 0.039 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 9.138181e-01 | 0.039 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.138181e-01 | 0.039 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 9.142949e-01 | 0.039 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 9.142949e-01 | 0.039 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.144442e-01 | 0.039 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.148151e-01 | 0.039 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 9.160946e-01 | 0.038 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.162599e-01 | 0.038 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 9.166597e-01 | 0.038 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 9.192960e-01 | 0.037 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.192960e-01 | 0.037 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 9.192960e-01 | 0.037 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 9.195857e-01 | 0.036 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.201638e-01 | 0.036 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.225368e-01 | 0.035 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 9.225368e-01 | 0.035 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 9.225368e-01 | 0.035 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 9.225368e-01 | 0.035 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.225368e-01 | 0.035 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.225368e-01 | 0.035 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.225368e-01 | 0.035 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.239852e-01 | 0.034 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.254514e-01 | 0.034 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.259649e-01 | 0.033 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.259649e-01 | 0.033 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 9.265273e-01 | 0.033 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.266295e-01 | 0.033 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 9.294898e-01 | 0.032 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.303172e-01 | 0.031 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.303739e-01 | 0.031 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.303739e-01 | 0.031 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.303739e-01 | 0.031 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 9.303739e-01 | 0.031 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 9.303739e-01 | 0.031 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.303739e-01 | 0.031 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.303739e-01 | 0.031 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 9.303739e-01 | 0.031 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 9.303739e-01 | 0.031 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.304216e-01 | 0.031 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.304216e-01 | 0.031 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.304216e-01 | 0.031 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 9.321110e-01 | 0.031 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.321110e-01 | 0.031 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.321110e-01 | 0.031 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 9.321110e-01 | 0.031 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.350903e-01 | 0.029 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 9.357299e-01 | 0.029 | 1 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 9.358090e-01 | 0.029 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.367254e-01 | 0.028 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 9.367548e-01 | 0.028 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.374186e-01 | 0.028 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 9.374186e-01 | 0.028 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 9.374186e-01 | 0.028 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.374186e-01 | 0.028 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 9.374186e-01 | 0.028 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 9.374186e-01 | 0.028 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.374186e-01 | 0.028 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 9.374186e-01 | 0.028 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.374186e-01 | 0.028 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.377718e-01 | 0.028 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.377718e-01 | 0.028 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.377718e-01 | 0.028 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 9.394729e-01 | 0.027 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 9.398396e-01 | 0.027 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.398396e-01 | 0.027 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 9.401351e-01 | 0.027 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 9.404020e-01 | 0.027 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.410624e-01 | 0.026 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 9.417088e-01 | 0.026 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.429825e-01 | 0.025 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.429825e-01 | 0.025 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 9.433554e-01 | 0.025 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 9.435071e-01 | 0.025 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 9.435071e-01 | 0.025 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 9.437509e-01 | 0.025 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 9.437509e-01 | 0.025 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 9.437509e-01 | 0.025 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.437509e-01 | 0.025 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.437509e-01 | 0.025 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 9.437509e-01 | 0.025 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.456294e-01 | 0.024 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.457806e-01 | 0.024 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.457806e-01 | 0.024 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 9.464219e-01 | 0.024 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 9.464219e-01 | 0.024 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.475865e-01 | 0.023 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.477764e-01 | 0.023 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.477764e-01 | 0.023 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.494427e-01 | 0.023 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.494427e-01 | 0.023 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.494427e-01 | 0.023 | 0 | 0 |
| Reactions specific to the complex N-glycan synthesis pathway | R-HSA-975578 | 9.494427e-01 | 0.023 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 9.494427e-01 | 0.023 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.494427e-01 | 0.023 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.494427e-01 | 0.023 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.495415e-01 | 0.022 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 9.498421e-01 | 0.022 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 9.519087e-01 | 0.021 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 9.519087e-01 | 0.021 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 9.528596e-01 | 0.021 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 9.543234e-01 | 0.020 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 9.545405e-01 | 0.020 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.545589e-01 | 0.020 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.545589e-01 | 0.020 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.545589e-01 | 0.020 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.545589e-01 | 0.020 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 9.547570e-01 | 0.020 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 9.562351e-01 | 0.019 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 9.591577e-01 | 0.018 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 9.591577e-01 | 0.018 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.591577e-01 | 0.018 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.591577e-01 | 0.018 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.597448e-01 | 0.018 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 9.599562e-01 | 0.018 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 9.599562e-01 | 0.018 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 9.599562e-01 | 0.018 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 9.599562e-01 | 0.018 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 9.603865e-01 | 0.018 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.603865e-01 | 0.018 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.605611e-01 | 0.017 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.616843e-01 | 0.017 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 9.619137e-01 | 0.017 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.632913e-01 | 0.016 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 9.632913e-01 | 0.016 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 9.632913e-01 | 0.016 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.632913e-01 | 0.016 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.632913e-01 | 0.016 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.632913e-01 | 0.016 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 9.632913e-01 | 0.016 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 9.633726e-01 | 0.016 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.633726e-01 | 0.016 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 9.634117e-01 | 0.016 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.634117e-01 | 0.016 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.645746e-01 | 0.016 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 9.659172e-01 | 0.015 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.665079e-01 | 0.015 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 9.667854e-01 | 0.015 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 9.670067e-01 | 0.015 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.670067e-01 | 0.015 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.670067e-01 | 0.015 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.670067e-01 | 0.015 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 9.688691e-01 | 0.014 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.689538e-01 | 0.014 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.689538e-01 | 0.014 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 9.693841e-01 | 0.014 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 9.693841e-01 | 0.014 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 9.703463e-01 | 0.013 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 9.703463e-01 | 0.013 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 9.703463e-01 | 0.013 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.703463e-01 | 0.013 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 9.703463e-01 | 0.013 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.703463e-01 | 0.013 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 9.703463e-01 | 0.013 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.703463e-01 | 0.013 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.703463e-01 | 0.013 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 9.703463e-01 | 0.013 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.703463e-01 | 0.013 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.708321e-01 | 0.013 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.720214e-01 | 0.012 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 9.733480e-01 | 0.012 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 9.733480e-01 | 0.012 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 9.733480e-01 | 0.012 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.733480e-01 | 0.012 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.734678e-01 | 0.012 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 9.744125e-01 | 0.011 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.744386e-01 | 0.011 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.744386e-01 | 0.011 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.755370e-01 | 0.011 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 9.760461e-01 | 0.011 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 9.760461e-01 | 0.011 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.760461e-01 | 0.011 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.775971e-01 | 0.010 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.782966e-01 | 0.010 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.784653e-01 | 0.009 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.784711e-01 | 0.009 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 9.786819e-01 | 0.009 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.786819e-01 | 0.009 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.786819e-01 | 0.009 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.786819e-01 | 0.009 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 9.805391e-01 | 0.009 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.805391e-01 | 0.009 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.806508e-01 | 0.008 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.806508e-01 | 0.008 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 9.806508e-01 | 0.008 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.806508e-01 | 0.008 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 9.806508e-01 | 0.008 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.812587e-01 | 0.008 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.812587e-01 | 0.008 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 9.816816e-01 | 0.008 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 9.821596e-01 | 0.008 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.825305e-01 | 0.008 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 9.826099e-01 | 0.008 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 9.835814e-01 | 0.007 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.843708e-01 | 0.007 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.848145e-01 | 0.007 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 9.859534e-01 | 0.006 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.859534e-01 | 0.006 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.859534e-01 | 0.006 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.859534e-01 | 0.006 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 9.862689e-01 | 0.006 | 0 | 0 |
| Translation | R-HSA-72766 | 9.863660e-01 | 0.006 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.865174e-01 | 0.006 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.865174e-01 | 0.006 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.872382e-01 | 0.006 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.873759e-01 | 0.006 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 9.873759e-01 | 0.006 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.873759e-01 | 0.006 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.873759e-01 | 0.006 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.881927e-01 | 0.005 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.886544e-01 | 0.005 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.886544e-01 | 0.005 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.887505e-01 | 0.005 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.898035e-01 | 0.004 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.898035e-01 | 0.004 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.908362e-01 | 0.004 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 9.908362e-01 | 0.004 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 9.908362e-01 | 0.004 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 9.908362e-01 | 0.004 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.908362e-01 | 0.004 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.917644e-01 | 0.004 | 0 | 0 |
| Depurination | R-HSA-73927 | 9.917644e-01 | 0.004 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.917644e-01 | 0.004 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.917644e-01 | 0.004 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 9.917644e-01 | 0.004 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.922788e-01 | 0.003 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 9.923052e-01 | 0.003 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.923650e-01 | 0.003 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.925987e-01 | 0.003 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.929653e-01 | 0.003 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.932000e-01 | 0.003 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.932000e-01 | 0.003 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 9.933485e-01 | 0.003 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.933485e-01 | 0.003 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.933485e-01 | 0.003 | 0 | 0 |
| N-glycan antennae elongation in the medial/trans-Golgi | R-HSA-975576 | 9.933485e-01 | 0.003 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.935776e-01 | 0.003 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.935945e-01 | 0.003 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.937313e-01 | 0.003 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.937313e-01 | 0.003 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.937313e-01 | 0.003 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.939746e-01 | 0.003 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 9.940223e-01 | 0.003 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.941685e-01 | 0.003 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.942746e-01 | 0.002 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.946280e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.946280e-01 | 0.002 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.946280e-01 | 0.002 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.946920e-01 | 0.002 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.951693e-01 | 0.002 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.954666e-01 | 0.002 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.956514e-01 | 0.002 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 9.956615e-01 | 0.002 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.957232e-01 | 0.002 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 9.958040e-01 | 0.002 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.960010e-01 | 0.002 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.961011e-01 | 0.002 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.961011e-01 | 0.002 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.961011e-01 | 0.002 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.961011e-01 | 0.002 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.964962e-01 | 0.002 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.968975e-01 | 0.001 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.969915e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.969915e-01 | 0.001 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 9.970118e-01 | 0.001 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.970576e-01 | 0.001 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.970599e-01 | 0.001 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.972408e-01 | 0.001 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.972624e-01 | 0.001 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.974292e-01 | 0.001 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.974572e-01 | 0.001 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.975347e-01 | 0.001 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.977038e-01 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.977150e-01 | 0.001 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.977150e-01 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.977396e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.978746e-01 | 0.001 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.979457e-01 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.981332e-01 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.981548e-01 | 0.001 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.983037e-01 | 0.001 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.983038e-01 | 0.001 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.987968e-01 | 0.001 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.988422e-01 | 0.001 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.988914e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.989188e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.989516e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.989516e-01 | 0.000 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.990285e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.990481e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.990481e-01 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.990656e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.991350e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.992156e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.993484e-01 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.993666e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.995244e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.995405e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.996029e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.996666e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.996666e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.996666e-01 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.996770e-01 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.996785e-01 | 0.000 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.997255e-01 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.997405e-01 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.997827e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.997827e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.997827e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.997827e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.998048e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.998214e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.998424e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.998424e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.998562e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.998650e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.998821e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.998892e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.998973e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.998996e-01 | 0.000 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.999255e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999303e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999324e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999435e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999608e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999615e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999663e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999695e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.999758e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999820e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999866e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999880e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.999892e-01 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.999901e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.999905e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999917e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999959e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999960e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999962e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999965e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999966e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999981e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999985e-01 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.999987e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999989e-01 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.999991e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999991e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999991e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999993e-01 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 9.999993e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999997e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999998e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.999998e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999998e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999999e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.999999e-01 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 9.999999e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000e+00 | 0.000 | 1 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |